Patent Grant
12102620
c-KIT (also known as KIT, CD117, and stem cell factor receptor) is a 145 kDa transmembrane tyrosine kinase protein that acts as a type-III receptor. The c-KIT proto-oncogene, located on chromosome 4q11-21, encodes the c-KIT receptor, whose ligand is the stem cell factor (SCF, steel factor, kit ligand, mast cell growth factor). The receptor has tyrosine-protein kinase activity, and binding of the ligand SCF leads to the autophosphorylation of c-KIT and its association with substrates such as phosphatidylinositol 3-kinase (PI3K). Tyrosine phosphorylation by protein tyrosine kinases is of particular importance in cellular signaling and can mediate signals for major cellular processes, such as proliferation, survival, differentiation, apoptosis, attachment, invasiveness and migration.
The receptor tyrosine kinase c-KIT gene is critical for mast cell growth, survival, differentiation and homeostasis. Activating mutations or overexpression of the c-KIT gene enhances the ability of the c-KIT receptor to initiate the intracellular pathways resulting in aberrant mast cell proliferation.
Mastocytosis is a rare disorder characterized by abnormal accumulations of mast cells (MCs) in the skin, bone marrow, and internal organs (e.g., liver, spleen, gastrointestinal tract and lymph nodes). Cases beginning during adulthood tend to be chronic and involve the bone marrow in addition to the skin, whereas, during childhood, the condition is often marked by skin manifestations with no internal organ involvement and can often resolve during puberty. In most adult patients, mastocytosis tends to be persistent, and may progress into a more advanced category in a minority of patients. Mastocytosis can be classified to a specific type depending on the patient's symptoms and overall presentation. Types of mastocytosis include cutaneous mastocytosis (e.g., maculopapular cutaneous mastocytosis, mastocytoma, and diffuse cutaneous mastocytosis) and systemic mastocytosis (e.g., indolent systemic mastocytosis (ISM), systemic smoldering mastocytosis (SSM), systemic mastocytosis with associated clonal hematological non-mast cell lineage disease (SM-AHN), aggressive systemic mastocytosis (ASM), mast cell leukemia (MCL) and mast cell sarcoma). In rare cases, outgrowth of aggressive neoplastic mast cells results in end organ failure where the patients have significantly reduced lifespan and require cytoreductive therapy. The pathologic accumulation of neoplastic mast cells caused by oncogenic mutations of c-KIT was found to be causative of systemic mastocytosis. The predominant activating KIT mutation is the aspartic acid to valine substitution at residue 816 (KIT D816V). Patients with systemic mastocytosis, whose mast cells frequently contain the activating D816V c-KIT mutation, may have indolent to aggressive diseases, and they may experience mast cell mediator release related symptoms. Indolent systemic mastocytosis with recurrent anaphylaxis or vascular collapse in the absence of skin lesions is a specific subtype indolent systemic mastocytosis, and this clonal MC activation disorder represents a significant fraction of all mast cell activation syndromes. The V560G KIT mutation is extremely rare in patients with systemic mastocytosis, and its biological and prognostic impact is unclear. Currently, most tyrosine kinase inhibitors have demonstrated only modest efficacy in advanced disease states and are accompanied by significant side effects. Additionally, some aggressive KIT mutations, including the KIT D816V mutation, are resistant to classical ATP competitive KIT inhibitors such as imatinib, sunitinib, sorafenib, and regorafenib. Midostaurin, an inhibitor of c-KIT D816V, was recently approved for the treatment of SM in 2017.
While the c-KIT D816V mutation is the primary c-KIT mutation reported as a driver of systemic mastocytosis (SM), secondary c-KIT mutations that confer resistance to certain c-KIT inhibitors (“secondary resistance c-KIT mutations”) have also been reported in mastocytosis patients, including, e.g., a Y269C, Y503_F504insAY, V560D, or K642E point mutation, an in-frame deletion or insertion, or a missense mutation in the c-KIT gene.
Activating mutations or overexpression of the c-KIT gene are linked to neoplastic mast cell proliferation. Given the complex function of c-KIT and the potential utility for c-KIT inhibitors in treating drug resistant systematic mastocytosis, there is a need for inhibitors and therapeutic treatments with advantageous therapeutic properties.
The present disclosure, in part, relates to the use of a c-KIT inhibitor, e.g., 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3- yl]-2-fluorophenyl]-3-phenylurea (Compound A), and a MAPKAP pathway inhibitor, e.g., a MEK inhibitor such as trametinib, or an ERK inhibitor such as ulixertinib, or a RAF inhibitor such as LY3009120, for inducing the apoptosis of mastocytosis cells.
Also provided in the present disclosure are methods of treating mastocytosis in a patient in need thereof, comprising administering to the patient: an effective amount of a c-KIT inhibitor, e.g., 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea (Compound A as described herein); and an effective amount of an inhibitor of a mitogen-activated protein kinase (MEK inhibitor), and/or an effective amount of an extracellular signal regulated kinase inhibitor (ERK inhibitor).
For example, provided herein is a method of treating a systemic mastocytosis in a patient in need thereof, comprising administering to the patient: an effective amount of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea, or a pharmaceutically acceptable salt thereof; and an effective amount of an inhibitor of a mitogen-activated protein kinase (MEK inhibitor) or ERK inhibitor.
Also contemplated in this disclosure is a method of treating mastocytosis in a patient in need thereof, comprising administering to the patient: an effective amount of a c-KIT inhibitor; and an effective amount of a RAF inhibitor.
It is found that the combination of a c-KIT inhibitor, e.g., 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2- fluorophenyl]-3-phenylurea (Compound A), and a MAPKAP pathway inhibitor, e.g., the MEK inhibitor trametinib, or the ERK inhibitor ulixertinib, or the RAF inhibitor LY3009120 unexpectedly synergizes to induce apoptosis of mastocytosis cells, as demonstrated in the accompanying Examples. In addition, the combination therapy methods disclosed herein are cytocidal as opposed to being merely cytostatic.
Without wishing to be bound to any particular theory, it is believed that many c-KIT inhibitors only inhibit certain mutant forms of c-KIT and do not effectively inhibit the c-KIT D816V mutation that is causative of SM. The present disclosure provides methods of treating c-KIT-mediated mastocytosis, by inhibiting both c-KIT and MEK, using a c-KIT inhibitor in combination with a MAPKAP pathway inhibitor. In particular embodiments, the c-KIT inhibitor is disclosed herein as Compound A or a pharmaceutically acceptable salt thereof, Compound B or a pharmaceutically acceptable salt thereof, midostaurin or a pharmaceutically acceptable salt thereof, BLU-285 or a pharmaceutically acceptable salt thereof, PLX9486 or a pharmaceutically acceptable salt thereof, or crenolanib or a pharmaceutically acceptable salt thereof. Surprisingly, the c-KIT inhibitor, e.g., Compound A and Compound B (and pharmaceutically acceptable salts thereof), synergizes with the MEK, ERK,or RAF, inhibitor to inhibit proliferation and induce apoptosis of mastocytosis cells.
Accordingly, in certain embodiments, the present disclosure provides methods for inducing inducing cytocidal mast cell killing, inducing apoptosis of mast cells, inhibiting growth or proliferation of mast cells, inhibiting mast cell mediator release, reducing the amount of accumulated mast cells in a tissue or organ, reducing the volume of a mastocytosis-related tumor, such as a mast cell leukemia or mast cell sarcoma, and/or inhibiting mast cell regrowth, by contacting mast cells, e.g., mast cells comprising a c-KIT mutation, with a c-KIT inhibitor and a MAPKAP pathway inhibitor. In various embodiments, the mast cells are contacted in vitro, in vivo, or ex vivo. In particular embodiments, the c-KIT inhibitor is disclosed herein as Compound A or a pharmaceutically acceptable salt thereof, Compound B or a pharmaceutically acceptable salt thereof, midostaurin or a pharmaceutically acceptable salt thereof, BLU-285 or a pharmaceutically acceptable salt thereof, PLX9486 or a pharmaceutically acceptable salt thereof, or crenolanib or a pharmaceutically acceptable salt thereof; and the MEK inhibitor disclosed herein as trametinib, cobimetinib, selumetinib, or binimetinib; ERK inhibitors including but not limited to ulixertinib, SCH772984, LY3214996, ravoxertinib, and VX-11e, and RAF inhibitors including but not limited to LY3009120, vemurafenib, or dabrafenib.
In certain embodiments, the present disclosure includes methods for treating a subject having a mastocytosis, a mast cell leukemia, or an acute myeloid leukemia, comprising administering to the subject an effective amount of: (i) a KIT inhibitor, e.g., 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin- 3-yl]-2-fluorophenyl]-3-phenylurea or a pharmaceutically acceptable salt thereof, or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3- phenylurea or a pharmaceutically acceptable salt thereof; and (ii) a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib. In particular embodiments of any of the methods disclosed herein, the mastocytosis is a systemic mastocytosis resulting from a D816V mutation of the c-KIT gene in mast cells.
Definitions
“Compounds A and B” as used herein refer to 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]- 3-phenylurea and 1-(5-(7-amino-l-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, respectively. Pharmaceutically acceptable salts, tautomers, hydrates, and solvates, of Compounds A and B are also contemplated in this disclosure. The structures of Compounds A and B are represented below:
Methods of making Compound A and Compound B are disclosed in U.S. Pat. No. 8,461,179B1, the contents of which are incorporated herein by reference.
Illustrative methods and materials are described herein. In the specification and the appended claims, the singular forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.
Throughout this disclosure, various patents, patent applications and publications are referenced. The disclosures of these patents, patent applications and publications in their entireties are incorporated into this disclosure by reference in order to more fully describe the state of the art as known to those skilled therein as of the date of this disclosure. This disclosure will govern in the instance that there is any inconsistency between the patents, patent applications and publications and this disclosure. For convenience, certain terms employed in the specification, examples and claims are collected here. Unless defined otherwise, all technical and scientific terms used in this disclosure have the same meanings as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The initial definition provided for a group or term provided in this disclosure applies to that group or term throughout the present disclosure individually or as part of another group, unless otherwise indicated.
“Pharmaceutically acceptable carrier, diluent or excipient” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
“Pharmaceutically acceptable salt” includes acid addition salts.
“Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, undecylenic acid, and the like.
A “pharmaceutical composition” refers to a formulation of a compound described herein (e.g., Compound A or a pharmaceutically acceptable salt thereof) and a medium generally accepted in the art for the delivery of the biologically active compound to mammals, e.g., humans. Such a medium includes all pharmaceutically acceptable carriers, diluents or excipients therefor.
A “MAPKAP pathway inhibitor” is an inhibitor of the MAP kinase signaling pathway. Inhibitors of this pathway include RAS inhibitors, RAF inhibitors (e.g. vemurafenib, dabrafenib, LY3009120), MEK inhibitors (e.g. trametinib, binimetinib, cobimetinib), and ERK inhibitors (e.g. ulixertinib).
Subjects or patients “in need of treatment” with a combination therapy of the present disclosure, e.g., a c-KIT inhibitor in combination with a MAPKAP pathway inhibitor, include subjects with diseases and/or conditions that can be treated with a combination disclosed herein to achieve a beneficial therapeutic result, e.g., a mastocytosis, mast cell leukemia, or acute myeloid leukemia. A beneficial outcome in the treatment of mastocytosis may include a complete response, a partial response, a clinical improvement, or stable disease as defined by IWG-MRT-ECNM criteria (Gotlib et al, Blood 2013; 121: 2393-401). In certain embodiments, a subject in need of treatment is suffering from a cutaneous inastocytosis maculopapular cutaneous mastocytosis, mastocytorna, and diffuse cutaneous mastocytosis) or a systemic mastocytosis (e.g., indolent systemic mastocytosis, systemic smoldering mastocytosis, systemic mastocytosis with associated clonal. hematological non-mast cell lineage disease, aggressive systemic mastocytosis, mast cell leukemia and mast cell sarcoma). In particular embodiments, subjects are mammals, e.g., humans or other mammals.
The term “effective amount” when used in connection with a compound or other therapeutic agent disclosed herein, refers to an amount of the therapeutic agent, e.g., Compound A or a MAPKAP pathway inhibitor, alone or in combination, that is useful to treat or prevent a disease or disorder. The effective amount of therapeutic agents used in a combination therapy is the amount of each of the therapeutic agents that is useful for treating or preventing a disease or disorder when used in the combination therapy, even if the amount of one or both of the therapeutic agents, in the absence of the other therapeutic agent, is ineffective to treat or prevent the disease or disorder. In certain embodiments, an effective amount is a quantity that results in inducing cytocidal mast cell killing, inducing apoptosis of mast cells, reducing the amount of accumulated mast cells in a tissue or organ, reducing mastocytosis symptoms, inhibiting mast cell mediator release, inhibiting the growth of mast cells, and/or inducing mastocytosis regression wherein mast cells harbor activating mutations in c-KIT kinase including the activating c-KIT D816V mutation. The “effective amount” can vary depending upon the mode of administration, specific locus of the disease or disorder, and the age, body weight, and general health of the subject. The amount of the compounds administered will depend on the degree, severity, and type of the disease or condition, the amount of therapy desired, and the release characteristics of the pharmaceutical formulation(s). It will also depend on the subject's health, size, weight, age, sex and tolerance to drugs. Typically, the compounds are administered for a sufficient period of time to achieve the desired therapeutic effect.
The terms “treatment,” “treat,” and “treating,” are meant to include the full spectrum of intervention in patients being treated, e.g., patients with a mastocytosis or acute myeloid leukemia (AML). Treating can be curing, improving, or at least partially ameliorating the disorder. In particular embodiments, treatment is performed with the intention to induce cytocidal mast cell killing, induce apoptosis of mast cells, reduce the amount of accumulated mast cells in a tissue or organ, reduce mastocytosis symptoms, inhibit mast cell mediator release, inhibit the growth of mast cells, and/or induce mastocytosis regression in the subject being treated. In certain embodiments, treatment with a combination therapy disclosed herein alleviates, slows or reverses one or more of the mastocytosis symptoms and/or induces regression of the mastocytosis, even if the mastocytosis is not actually eliminated. In some embodiments, treatment includes eliminating the disease or disorder, e.g., mastocytosis or AML, entirely. In other embodiments, treatment results in a complete response, a partial response, a clinical improvement, or stable disease as defined by IWG-MRT-ECNM criteria (Gotlib et al., Blood 2013; 121: 2393-401).
“Mast cells” as used herein, include mast cells (also called mastocytes) CD34-H mast cell precursor cells.
“Neoplasm” as used herein refers to an abnormal tissue that grows by cellular proliferation more rapidly than normal. Neoplasms show partial or complete lack of structural organization and functional coordination with the normal tissue, and usually form a distinct mass of tissue that may be either benign (benign tumor) or malignant (cancer).
“Tumor” as used herein refers to a mass. This is a term that may refer to benign (generally harmless) or malignant (cancerous) growths. Malignant growth can originate from a solid organ or the bone marrow. The latter is often referred to as liquid tumors. “Tumors” encompass mast cell leukemias and mast cell sarcomas, collectively referred to herein as “mastocytosis tumors.”
In certain embodiments, the therapeutic effect of treating a mastocytosis according to the methods disclosed herein may be measured using standard response criteria known in the art. For example, “response criteria for complete remission (CR), partial remission (PR), clinical improvement (CI) or stable disease (SD)” used to quantitate the effects of therapy on aggressive systemic mastocytosis, mast cell leukemia, and systemic mastocytosis associated with a myeloid neoplasm may be any of those criteria defined by the IWG-MRT-ECNM (Gotlib et al, Blood 2013; 121: 2393-401). For example, Complete remission (CR) requires all 4 criteria and response duration must be≥12 wk, no presence of compact neoplastic mast cell aggregates in the BM or other biopsied extracutaneous organ. Serum tryptase level<20 ng/m14, peripheral blood count remission defined as ANC≥1×109/with normal differential, Hb level≥11 g/dL, and platelet count≥100×109/L, and complete resolution of palpable hepatosplenomegaly and all biopsy-proven or suspected SM-related organ damage (CI findings); Partial remission (PR)* requires all 3 criteria and response duration must be≥12 wk, in the absence of both CR and progressive disease (PD) with: reduction by≥50% in neoplastic MCs in the marrow and/or or other extracutaneous organ at biopsy demonstrating eligible SM-related organ damage, reduction of serum tryptase level by≥50%; and resolution of 1 or more biopsy-proven or suspected SM-related organ damage (CI finding(s)); clinical improvement (CI) is where response duration must be≥12 wk, requires 1 or more of the nonhematologic and/or hematologic response criteria to be fulfilled (see Table 3) in the absence of both CR/PR, and assignment or progressive disease (PD). Stable disease (SD) is not meeting criteria for CR, PR, CI, or PD.
Guidelines for adjudicating response include (1) Only disease-related≥grade 2 organ damage is evaluable as a primary endpoint in clinical trials. (2) Response adjudications of CR, PR, SD, PD, and loss or response (LOR) should only be applied to these ≥grade 2 organ damage findings in the context of trials. (3) Disease status at the time of patient removal from the study singularly relates to the updated status of initial≥grade 2 organ damage finding(s). (4) Exclusion of drug-related toxicity and/or other clinical issues (e.g., gastrointestinal tract bleeding in the case of worsening anemia/transfusion-dependence) should be undertaken before assigning the designation PD or LOR in a patient with worsening of baseline≥grade 2 organ damage.
In certain embodiments, the therapeutic effect of treating an AML according to the methods disclosed herein may be measured using standard response criteria known in the art. For example, “response criteria for the treatment of AML” used to quantitate effects of therapy on AML may be any of those criteria defined below, including complete remission (CR) without minimal residual disease (CRMRD-), Complete remission (CR), CR with incomplete hematologic recovery (CRi), Morphologic leukemia-free state (MLFS), Partial remission (PR), stable disease (SD), or progressive disease (PD), as defined by Blood. 2017 Jan. 26; 129(4): 424-447, and summarized as: Complete Remission without minimal residual disease (CRMRD-): If studied pretreatment, CR with negativity for a genetic marker by RT-qPCR, or CR with negativity by MFC; Complete remission (CR): Bone marrow blasts<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count (ANC)≥1.0×109/L [1000/μL]); platelet count≥100×109/L [100 000/μL]); CR with incomplete hematologic recovery (CRi): All CR criteria except for residual neutropenia (<1.0×109/L [1000/μL]) or thrombocytopenia (<100×109/L [100 000/μL]); Morphologic leukemia-free state (MLFS): Bone marrow blasts<5%; absence of blasts with Auer rods; absence of extramedullary disease; no hematologic recovery required; Partial remission (PR): All hematologic criteria of CR; decrease of bone marrow blast percentage to 5% to 25%; and decrease of pretreatment bone marrow blast percentage by at least 50%.
A “combination therapy” is a treatment that includes the administration of two or more therapeutic agents, e.g., a c-KIT inhibitor (such as Compound A or a pharmaceutically acceptable salt thereof, midostaurin, BLU-285, PLX9486, or crenolanib) and a MAPKAP pathway inhibitor (including but not limited to trametinib, cobimetinib, selumetinib, binimetinib, ulixertinib, LY3009120), to a patient. The two or more therapeutic agents may be delivered at the same time, e.g., in separate pharmaceutical compositions or in the same pharmaceutical composition, or they may be delivered at different times. For example, they may be delivered concurrently or during overlapping time periods, and/or one therapeutic agent may be delivered before or after the other therapeutic agent(s). Treatment with a combination of a KIT inhibitor such as Compound A and a MAPKAP pathway inhibitor optionally includes treatment with either single agent, preceded or followed by a period of concurrent treatment with both agents. However, it is contemplated that during some time period, effective amounts of the two or more therapeutic agents are present within the patient.
Methods of Treatment
In one embodiment, the present disclosure provides methods of treating or preventing a mastocytosis, optionally a c-KIT-mediated mastocytosis, e.g., a systemic mastocytosis (SM), comprising providing to or administering to a subject in need thereof an effective amount of a c-KIT inhibitor in combination with an effective amount of a MAPKAP pathway inhibitor, e.g., trametinib, cobimetinib, selumetinib, binimetinib, ulixertinib, or LY3009120. In one embodiment, the present disclosure provides methods of treating or preventing a mastocytosis, optionally a c-KIT-mediated mastocytosis, e.g., a systemic mastocytosis (SM), comprising providing to or administering to a subject in need thereof an effective amount of Compound A (or a pharmaceutically acceptable salt thereof) or Compound B (or a pharmaceutically acceptable salt thereof), in combination with an effective amount of a a MAPKAP pathway inhibitor, e.g., trametinib, cobimetinib, selumetinib, binimetinib, ulixertinib, or LY3009120. In a related embodiment, the present disclosure provides methods of treating or preventing a mastocytosis tumor, optionally a c-KIT-mediated mastocytosis tumor, e.g., a mast cell leukemia or mast cell sarcoma, comprising providing to or administering to a subject in need thereof an effective amount of a c-KIT inhibitor in combination with an effective amount of a a MAPKAP pathway inhibitor, e.g., trametinib, cobimetinib, selumetinib, binimetinib, ulixertinib, or LY3009120. In a related embodiment, the present disclosure provides methods of treating or preventing a mastocytosis tumor, optionally a c-KIT-mediated mastocytosis tumor, e.g., a mast cell leukemia or mast cell sarcoma, comprising providing to or administering to a subject in need thereof an effective amount of Compound A (or a pharmaceutically acceptable salt thereof) or Compound B (or a pharmaceutically acceptable salt thereof), in combination with an effective amount of a a MAPKAP pathway inhibitor, e.g., trametinib, cobimetinib, selumetinib, binimetinib, ulixertinib, or LY3009120.
In another example, the present disclosure provides a method of treating mastocytosis in a patient in need thereof, comprising administering to the patient: an effective amount of a c-KIT inhibitor; and an effective amount of one or more MAPKAP pathway inhibitors. Such a MAPKAP pathway inhibitor can be selected from the group consisting of a rapidly accelerated fibrosarcoma (RAF) kinase inhibitor, an inhibitor of a mitogen-activated protein kinase (MEK inhibitor), and an extracellular signal regulated kinase inhibitor (ERK inhibitor).
In one embodiment of such a disclosed method, the mastocytosis has a c-KIT mutation. In some embodiments, the c-KIT mutation is an activating mutation.
The mastocytosis may, in another embodiment, comprise mast cells having a primary mutation in exon 17 of a c-KIT gene. In some embodiments, the primary mutation is a c-KIT D816 mutation. In some embodiments, the primary mutation is one of D816V, D816Y, D816F, D816H, F522C, K5091, V560G, V559G, and de1419. In some embodiments, the primary mutation is D816V.
The mastocytosis may also comprise mast cells having a secondary c-KIT mutation. In some embodiments, the secondary c-KIT mutation is in one of exon 9, 11, 13 or 17. In some embodiments, the secondary c-KIT mutation is one of Y269C, Y503_F504insAY, V560D, or K642E mutation.
This disclosed method may further comprise determining if the mastocytosis has the c-KIT primary mutation. For example, the method further comprises determining if the mastocytosis has the c-KIT secondary mutation. In some embodiments, determining if the mastocytosis has the c-KIT primary or secondary mutation comprises identifying mutations in DNA extracted from a tumor sample. In yet another embodiment, determining if the mastocytosis has the c-KIT primary or secondary mutation comprises identifying mutations in circulating tumor DNA or from identifying mutations in circulating peripheral blood leukocytes.
The mastocytosis may be systemic mastocytosis. In some embodiments, the systemic mastocytosis is selected from the group consisting of indolent systemic mastocytosis, systemic smoldering mastocytosis, systemic mastocytosis with associated clonal hematological non-mast cell lineage disease, aggressive systemic mastocytosis, mast cell leukemia, and mast cell sarcoma. In some embodiments, the mastocytosis is indolent systemic mastocytosis, optionally systemic mastocytosis with recurrent anaphylaxis or vascular collapse in the absence of skin lesions. In some embodiments, the mastocytosis is systemic smoldering mastocytosis.
In some embodiments, the mastocytosis is systemic mastocytosis with associated clonal hematological non-mast cell lineage disease. In some embodiments, the mastocytosis is aggressive systemic mastocytosis. In some embodiments, the mastocytosis is mast cell leukemia or mast cell sarcoma. In some embodiments, the mastocytosis is cutaneous mastocytosis. In some embodiments, the mastocytosis is selected from the group consisting of: maculopapular cutaneous mastocytosis, mastocytoma, or diffuse cutaneous mastocytosis.
In such a disclosed method, the c-KIT inhibitor can be selected from the group consisting of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or a pharmaceutically acceptable salt thereof, midostaurin or a pharmaceutically acceptable salt thereof, imatinib mesylate, sunitinab malate, midostaurin, regorafenib, crenolanib, PTX9486, or BLU-285 (avapritinib) or a pharmaceutically acceptable salt thereof.
Furthermore, the MEK inhibitor can be selected from the group consisting of trametinib, selumetinib, cobimetinib, and binimetinib. In some embodiments, the MEK inhibitor is binimetinib. In some embodiments, the MEK inhibitor is trametinib. In some embodiments, the ERK inhibitor is selected from the group consisting of ulixertinib, SCH772984, and LY3214996. In some embodiments, the c-KIT inhibitor and the MEK and/or ERK inhibitor are administered substantially concurrently or sequentially.
The method may also comprise administering another cancer-targeted therapeutic agent, cancer-targeted biological, immune checkpoint inhibitor, or chemotherapeutic agent.
Additionally, two weeks or more of administration of an effective amount of a c-KIT inhibitor; and an effective amount of an inhibitor of a mitogen-activated protein kinase (MEK inhibitor), and/or an effective amount of an extracellular signal regulated kinase inhibitor (ERK inhibitor) in accordance with the contemplated method can result in the patient having at least a partial remission.
Also provided is a method of treating a systemic mastocytosis in a patient in need thereof, comprising administering to the patient: an effective amount of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]- 2-fluorophenyl]-3-phenylurea, or a pharmaceutically acceptable salt thereof; and an effective amount of a MAPKAP pathway inhibitor. In such a disclosed method, the MAPKAP pathway inhibitor is selected from the group consisting of rapidly accelerated fibrosarcoma (RAF) kinase inhibitor, an inhibitor of a mitogen-activated protein kinase (MEK inhibitor) and an extracellular signal regulated kinase inhibitor (ERK inhibitor).
The systemic mastocytosis can, in an embodiment, have a c-KIT mutation. For example, the mutation can be a c-KIT D816 mutation. In some embodiments, the mutation is one of D816V, D816Y, D816F, D816H, F522C, K5091, V560G, V559G, and de1419. In some embodiments, the mutation is one of: A553D, C433Y, D419Y, D572A, D816F, D816H,D816I, D816V, D816Y, D820G, de1419, dup(501-502), E839K, F522C, I817V, InsFF419, InsV815-I816, K5091, N8221, R815K, T417V, V560G, V5591 or Y418Y. In some embodiments, the mutation is D816V.
In addition, the mastocytosis may have a further c-KIT mutation that is one of Y269C, Y503_F504insAY, V560D, or K642E mutation.
In such a disclosed method, the MEK inhibitor can be selected from the group consisting of trametinib, selumetinib, cobimetinib, and binimetinib. In some embodiments, the MEK inhibitor is binimetinib. In some embodiments, the MEK inhibitor is trametinib. The ERK inhibitor can be selected from the group consisting of ulixertinib, SCH772984, and LY3214996.
The present disclosure additionally provides a method of treating mastocytosis in a patient in need thereof, comprising administering to the patient: an effective amount of a c-KIT inhibitor; and an effective amount of a RAF inhibitor.
In such a disclosed method, the RAF inhibitor can be a pan-RAF or B-RAF inhibitor including vemurafenib, dabrafenib, and LY3009120. Furthermore, the c-KIT inhibitor can be 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea, or a pharmaceutically acceptable salt thereof.
In specific embodiments of methods disclosed herein, including methods of treating a mastocytosis or a mastocytosis tumor, the methods include: induction of cytocidal mast cell killing, induction of apoptosis of mast cells, reduction of the amount of accumulated mast cells in a tissue or organ, reduction of mastocytosis symptoms, inhibition of mast cell mediator release, inhibition of the growth of mast cells, and/or induction of mastocytosis regression, wherein the mast cells harbor one or more activating mutations in c-KIT kinase, such as, e.g., the activating KIT D816V mutation. In certain embodiments, the methods encompass methods for eradicating a mastocytosis, e.g., a mastocytosis tumor, in a subject. In some embodiments, treatment results in a complete response, a partial response, a clinical improvement, or stable disease as defined by IWG-MRT-ECNM criteria (Gotlib et al, Blood 2013; 121: 2393-401).
In another related embodiment, the present disclosure provides methods of treating or preventing an acute myeloid leukemia (AML), optionally a c-KIT-mediated (AML), comprising administering to a subject in need thereof an effective amount of a c-KIT inhibitor in combination with an effective amount of a a MAPKAP pathway inhibitor, e.g., trametinib, cobimetinib, selumetinib, binimetinib, ulixertinib, or LY3009120. In a related embodiment, the present disclosure provides methods of treating or preventing an acute myeloid leukemia (AML), optionally a c-KIT-mediated (AML), comprising administering to a subject in need thereof an effective amount of Compound A (or a pharmaceutically acceptable salt thereof) or Compound B (or a pharmaceutically acceptable salt thereof), in combination with an effective amount of a a MAPKAP pathway inhibitor, e.g., trametinib, cobimetinib, selumetinib, binimetinib, ulixertinib, or LY3009120.
Where the methods described herein refer to treatment with Compound A or a pharmaceutically acceptable salt thereof, or with Compound B or a pharmaceutically acceptable salt thereof, it is meant that only one of Compound A or a pharmaceutically acceptable salt thereof, or Compound B or a pharmaceutically acceptable salt thereof is required. However, it is understood that these methods also encompass administering to a patient both Compound A or a pharmaceutically acceptable salt thereof, and Compound B or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor. The methods described herein also encompass administration of Compound A and a MAPKAP pathway inhibitor to a subject whereupon Compound A is metabolized in vivo to Compound B, and the in vivo mixture of Compound A and Compound B effectively treats a subject in combination with the MAPKAP pathway inhibitor.
Particular embodiments of the disclosed methods and compositions are practiced using: a combination of Compound A or a pharmaceutically acceptable salt thereof and trametinib; a combination of Compound A or a pharmaceutically acceptable salt thereof and selumetinib; a combination of Compound A or a pharmaceutically acceptable salt thereof and cobimetinib; or a combination of Compound A or a pharmaceutically acceptable salt thereof and binimetinib.
In one embodiment, Compound A or a pharmaceutically acceptable salt thereof and a MEK inhibitor, e.g., trametinib or binimetinib, are administered to a subject with a c-KIT-mediated mastocytosis. In another embodiment, Compound B or a pharmaceutically acceptable salt thereof and a MEK inhibitor, e.g., trametinib or binimetinib, are administered to a subject with a c-KIT-mediated mastocytosis.
In a related embodiment, Compound A or a pharmaceutically acceptable salt thereof and a MEK inhibitor, e.g., trametinib or binimetinib, are administered to a patient with a mastocytosis tumor, including but not limited to mast cell leukemia or a mast cell sarcoma, wherein mastocytosis tumor growth or tumor progression is caused by a primary activating c-KIT mutation, e.g., the KIT D816V mutation. In another embodiment, Compound B or a pharmaceutically acceptable salt thereof and a MEK inhibitor, e.g., trametinib or binimetinib, are administered to a patient with a mastocytosis tumor, including but not limited to mast cell leukemia or a mast cell sarcoma, wherein mastocytosis tumor growth or tumor progression is caused by a primary activating c-KIT mutation, e.g., the KIT D816V mutation. In certain embodiments, Compound A or a pharmaceutically acceptable salt thereof, or Compound B or a pharmaceutically acceptable salt thereof and a MEK inhibitor, e.g., trametinib or binimetinib, are administered to a patient with AML, optionally wherein the AML is caused by a primary activating c-KIT mutation, e.g., a c-KIT exon 8 activating mutation, or a c-KIT exon 17 mutation, including but not limited to mutations at D816 or at N822 (Journal of Clinical Oncology 2006 24:24, 3904-3911).
Particular embodiments of the disclosed methods and compositions are practiced using: a combination of Compound A or a pharmaceutically acceptable salt thereof and ulixertinib; a combination of Compound A or a pharmaceutically acceptable salt thereof and SCH772984, e; a combination of Compound A or a pharmaceutically acceptable salt thereof and LY3214996; a combination of Compound A or a pharmaceutically acceptable salt thereof and ravoxertinib, or a combination of Compound A or a pharmaceutically acceptable salt thereof and and VX-11.
In one embodiment, Compound A or a pharmaceutically acceptable salt thereof and an ERK inhibitor, e.g., ulixertinib, are administered to a subject with a c-KIT-mediated mastocytosis. In another embodiment, Compound B or a pharmaceutically acceptable salt thereof and an ERK inhibitor, e.g., ulixertinib, are administered to a subject with a c-KIT-mediated mastocytosis.
In a related embodiment, Compound A or a pharmaceutically acceptable salt thereof and an ERK inhibitor, e.g., ulixertinib, are administered to a patient with a mastocytosis tumor, including but not limited to mast cell leukemia or a mast cell sarcoma, wherein mastocytosis tumor growth or tumor progression is caused by a primary activating c-KIT mutation, e.g., the KIT D816V mutation. In another embodiment, Compound B or a pharmaceutically acceptable salt thereof and an ERK inhibitor, e.g., ulixertinib, are administered to a patient with a mastocytosis tumor, including but not limited to mast cell leukemia or a mast cell sarcoma, wherein mastocytosis tumor growth or tumor progression is caused by a primary activating c-KIT mutation, e.g., the KIT D816V mutation. In certain embodiments, Compound A or a pharmaceutically acceptable salt thereof, or Compound B or a pharmaceutically acceptable salt thereof and an ERK inhibitor, e.g., ulixertinib, are administered to a patient with AML, optionally wherein the AML is caused by a primary activating c-KIT mutation, e.g., a c-KIT exon 8 activating mutation, or a c-KIT exon 17 mutation, including but not limited to mutations at D816 or at N822 (Journal of Clinical Oncology 2006 24:24, 3904-3911).
Particular embodiments of the disclosed methods and compositions are practiced using: a combination of Compound A or a pharmaceutically acceptable salt thereof and LY3009120; a combination of Compound A or a pharmaceutically acceptable salt thereof and dabrafenib; or a combination of Compound A or a pharmaceutically acceptable salt thereof and vemurafenib.
In one embodiment, Compound A or a pharmaceutically acceptable salt thereof and a RAF inhibitor, e.g., LY3009120, dabrafenib, or vemurafenib, are administered to a subject with a c-KIT-mediated mastocytosis. In another embodiment, Compound B or a pharmaceutically acceptable salt thereof and a RAF inhibitor, e.g., LY3009120, dabrafenib, or vemurafenib, are administered to a subject with a c-KIT-mediated mastocytosis. In a related embodiment, Compound A or a pharmaceutically acceptable salt thereof and a RAF inhibitor, e.g., LY3009120, dabrafenib, or vemurafenib, are administered to a patient with a mastocytosis tumor, including but not limited to mast cell leukemia or a mast cell sarcoma, wherein mastocytosis tumor growth or tumor progression is caused by a primary activating c-KIT mutation, e.g., the KIT D816V mutation. In another embodiment, Compound B or a pharmaceutically acceptable salt thereof and a RAF inhibitor, e.g., LY3009120, dabrafenib, or vemurafenib, are administered to a patient with a mastocytosis tumor, including but not limited to mast cell leukemia or a mast cell sarcoma, wherein mastocytosis tumor growth or tumor progression is caused by a primary activating c-KIT mutation, e.g., the KIT D816V mutation. In certain embodiments, Compound A or a pharmaceutically acceptable salt thereof, or Compound B or a pharmaceutically acceptable salt thereof and a RAF inhibitor, e.g., LY3009120, dabrafenib, or vemurafenib, are administered to a patient with AML, optionally wherein the AML is caused by a primary activating c-KIT mutation, e.g., a c-KIT exon 8 activating mutation, or a c-KIT exon 17 mutation, including but not limited to mutations at D816 or at N822 (Journal of Clinical Oncology 2006 24:24, 3904-3911).
Illustrative c-KIT inhibitors that may be used according to the disclosed methods and compositions include, but are not limited to, Compound A or a pharmaceutically acceptable salt there, Compound B or a pharmaceutically acceptable salt thereof, midostaurin, BLU-285, PLX9486, and crenolanib. Illustrative MEK inhibitors that may be used according to the disclosed methods and compositions include, but are not limited to, trametinib, selumetinib, cobimetinib, and binimetinib. Illustrative ERK inhibitors that may be used according to the disclosed methods and compositions include, but are not limited to, ulixertinib, SCH772984, LY3214996, ravoxertinib, and VX-11e. Illustrative RAF inhibitors that may be used according to the disclosed methods and compositions include, but are not limited to, LY3009120, dabrafenib, and vemurafenib.
Treatment with Compound A or a pharmaceutically acceptable salt thereof, or Compound B or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, encompasses administering Compound A or a pharmaceutically acceptable salt thereof, or Compound B or a pharmaceutically acceptable salt thereof, before, after, simultaneous with, or during an overlapping time period with administering the MAPKAP pathway inhibitor. It is understood that an effective amount of any of Compound A or a pharmaceutically acceptable salt thereof, Compound B or a pharmaceutically acceptable salt thereof, another c-KIT inhibitor, or a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, may be different when used in the combinations disclosed herein as compared to when any of these agents is used by itself for the same purpose, e.g., to treat or prevent mastocytosis or a mast cell tumor, e.g., a mast cell leukemia or AML. In particular embodiments, an effective amount of Compound A or a pharmaceutically acceptable salt thereof, or of Compound B or a pharmaceutically acceptable salt thereof, is a lower amount when administered as a combination therapy with a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, as compared to when it is administered as a monotherapy, e.g., to treat or prevent a mastocytosis or a mast cell tumor. In particular embodiments, an effective amount of a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, is a lower amount when administered in a combination therapy with Compound A or a pharmaceutically acceptable salt thereof, or when administered in a combination therapy with Compound B or a pharmaceutically acceptable salt thereof, e.g., to treat or prevent a mastocytosis or a mast cell tumor.
Any of the methods disclosed herein may further include determining that the mastocytosis cells, mast cell tumor, or AML being treated has one or more c-KIT gene mutations. Such a determination may be made by routine methods for determining the presence of a gene mutation in a biological sample, e.g., a bone marrow sample, a tissue sample, a peripheral blood sample, or a plasma sample, obtained from the subject. In addition, such a determination may be made by reviewing the results of tests performed to determine the presence of one or more c-KIT gene mutations in the biological sample obtained from the patient. In certain embodiments of any of the methods disclosed herein, the methods are performed on subjects wherein the mastocytosis, mast cell tumor, or AML has been identified as having one or more c-KIT gene mutations. The c-KIT gene mutations include but not limited to any of those specifically described herein. In certain embodiments of any of the methods disclosed herein, the methods are not performed on subjects wherein the mastocytosis, mast cell tumor, or AML has been identified as not having one or more c-KIT gene mutations.
In various aspects of any of the methods disclosed herein, treatment with either Compound A or a pharmaceutically acceptable salt thereof, or Compound B or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, induces cytocidal mast cell killing, induces apoptosis of mast cells, reduces the amount of accumulated mast cells in a tissue or organ, reduces mastocytosis symptoms, inhibits mast cell mediator release, inhibits the growth of mast cells, and/or induces mastocytosis regression wherein mast cells harbor activating mutations in c-KIT kinase including the activating KIT D816V mutation. Methods for measuring or determining amounts of apoptosis of mast cells, mast cell killing, inhibition of mast cell growth and proliferation, inhibition of mast cell mediator release, peripheral blood mutant KIT allele burden, eradication of mastocytosis and mastocytosis tumors, complete response, partial response, clinical improvement, or stable disease are known in the art and include any methods described herein.
In particular embodiments, treatment with a combination of: a c-KIT inhibitor, e.g., Compound A or a pharmaceutically acceptable salt thereof, or Compound B or a pharmaceutically acceptable salt thereof; and a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, results in an increased amount of apoptosis of mastocytosis cells or mast cells, as compared to the amount of apoptosis of mastocytosis cells or mast cells of the same type either untreated or treated with only a MAPKAP pathway inhibitor, or with only a c-KIT inhibitor, e.g., Compound A or Compound B. For example, apoptosis may be increased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least two-fold, at least three-fold, at least four-fold, at least five-fold, at least 10-fold, or at least 20-fold. In certain embodiments, amounts of apoptosis are determined by measuring caspase activity of KIT mutant mast cells or mast cell lines including the HMC1.2 mast cell line harboring the KIT D816V mutation.
In particular embodiments, treatment with a combination of: a c-KIT unhibitor, e.g., Compound A or a pharmaceutically acceptable salt thereof, or Compound B or a pharmaceutically acceptable salt thereof; and a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, results in a decreased accumulation of mast cells in skin or an internal organ, e.g., liver, spleen, bone marrow, and/or small intestine, as compared to the amount of accumulation of mast cells in the same organ either untreated or treated with only a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, or with only a c-KIT inhibitor, e.g., midostaurin, BLU-285, Compound A or Compound B. For example, the amount or number of mast cells accumulated within the organ may be decreased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.
In particular embodiments, treatment with a combination of: a c-KIT inhibitor, e.g., Compound A or a pharmaceutically acceptable salt thereof, or Compound B or a pharmaceutically acceptable salt thereof; and a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, results in a complete response as defined by as defined by IWG-MRT-ECNM criteria (Gotlib et al, Blood 2013; 121: 2393-401).
In particular embodiments, treatment with a combination of: a c-KIT inhibitor, e.g., Compound A or a pharmaceutically acceptable salt thereof, or Compound B or a pharmaceutically acceptable salt thereof; and a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, results in a partial response as defined by as defined by IWG-MRT-ECNM criteria (Gotlib et al, Blood 2013; 121: 2393-401).
In particular embodiments, treatment with a combination of: a c-KIT inhibitor, e.g., Compound A or a pharmaceutically acceptable salt thereof, or Compound B or a pharmaceutically acceptable salt thereof; and a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, results in clinical improvement as defined by as defined by IWG-MRT-ECNM criteria (Gotlib et al, Blood 2013; 121: 2393-401).
In particular embodiments, treatment with a combination of: a c-KIT inhibitor, e.g., Compound A or a pharmaceutically acceptable salt thereof, or Compound B or a pharmaceutically acceptable salt thereof; and a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, results in stable disease as defined by as defined by IWG-MRT-ECNM criteria (Gotlib et al, Blood 2013; 121: 2393-401).
In particular embodiments, treatment with a combination of: a c-KIT inhibitor, e.g., Compound A or a pharmaceutically acceptable salt thereof, or Compound B or a pharmaceutically acceptable salt thereof; and a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, induces apoptosis or inhibits the growth of resistant mastocytosis cells containing a secondary KIT mutation in addition to the KIT D816V primary mutation wherein the secondary KIT mutation includes but is not limited to Y269C, Y503_F504insAY, V560D, or K642E point mutation, an in-frame deletion or insertion, or a missense mutation in the c-KIT gene (Lasho et al, Br J Haematol 173, 153-156).
In particular embodiments, treatment with a combination of: a c-KIT inhibitor, e.g., Compound A or a pharmaceutically acceptable salt thereof, or Compound B or a pharmaceutically acceptable salt thereof; and a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, induces apoptosis or inhibits the growth of resistant mastocytosis cells containing mutations, e.g., resistance mutations, in other genes, including any of those disclosed herein. In certain embodiments, such other gene mutations may include NRas gain of function mutations (Haematologica 2011;96(03):459-463.doi:10.3324/haematol.2010.031690) or TET2 loss of function mutations (Leukemia 2009;23:900-04; Blood, 6 Dec. 2012; 120 (24): 4846-49). The presence of other epigenetic or transcriptional regulator mutations have been detected in SM, including DNMT3A, ASXL1 and CBL mutations in 12%, 12% and 4% of patients, respectively (PloS one. 2012;7:e43090). Additionally, some mastocytosis patients also present with mutations in the spliceosome machinery. Spliceosomes ensure the correct linear order of exons spliced in mRNAs. Hanssens et al. reported 23.6% SRSF2, 5.6% SF3B1 and 2.7% U2AF1 incidence of mutations in a group of 72 mastocytosis patients (Haematologica 2014; 99:830-35). Such mastocytoses having complex genomic drivers may benefit from a treatment disclosed herein with a combination of a c-KIT inhibitor and a MEK inhibitor as compared to no treatment or treatment with only a MEK inhibitor, e.g., trametinib, or with only a c-KIT inhibitor, e.g., Compound A or Compound B. For example, apoptosis may be increased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least two-fold, at least three-fold, at least four-fold, at least five-fold, at least 10-fold, or at least 20-fold. For example, the amount of growth or number of resistant mastocytosis cells may be inhibited by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.
In particular embodiments, resistant mastocytosis cells are resistant to apoptosis-mediated cell death or cytocidal activity by treatment with a c-KIT inhibitor, e.g., Compound A, Compound B, midostaurin, BLU-285, PLX9486, or crenolanib, and/or are resistant to apoptosis-mediated cell death or cytocidal activity by treatment with a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, when used as single agent therapies.
In particular embodiments, treatment with a combination of: a c-KIT inhibitor, e.g., either Compound A or a pharmaceutically acceptable salt thereof, or Compound B or a pharmaceutically acceptable salt thereof; in combination with a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, results in eradication of a mastocytosis, e.g., a matocytosis tumor. In particular embodiments, eradication of a mastocytosis means there is no longer any detectable mastocytosis in the patient. In particular embodiments, there is no detectable mastocytosis in the patient for at least twelve weeks, at least twenty-four weeks, at least one year, at least two years, or at least 5 years after initiation of treatment of the mastocytosis by a combination therapy disclosed herein. Eradication of mastocytosis may be determined by criteria for complete response as defined by IWG-MRT-ECNM criteria (Gotlib et al, Blood 2013; 121: 2393-401).
The present disclosure describes combination therapies that involve the administration of a c-KIT inhibitor, e.g., either Compound A or a pharmaceutically acceptable salt thereof, or Compound B or a pharmaceutically acceptable salt thereof, and a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120. The combination therapies described herein can be used by themselves, or in combination with one or more additional therapeutic agents. For example, either Compound A or a pharmaceutically acceptable salt thereof or Compound B or a pharmaceutically acceptable salt thereof, and a MAPKAP pathway inhibitor, can be administered together with a cancer targeted therapeutic agent, a cancer-targeted biologic, an immune checkpoint inhibitor, or a chemotherapeutic agent. In another embodiment, Compound A or Compound B and a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120are administered without any other therapeutic agent. The therapeutic agents can be administered together with or sequentially with another therapeutic agent described herein in a combination therapy.
Combination therapy can be achieved by administering two or more therapeutic agents, each of which is formulated and administered separately, or by administering two or more therapeutic agents in a single formulation. Other combinations are also encompassed by combination therapy. While the two or more agents in the combination therapy can be administered simultaneously, they need not be. For example, administration of a first agent (or combination of agents) can precede administration of a second agent (or combination of agents) by minutes, hours, days, or weeks. Thus, the two or more agents can be administered within minutes of each other or within 1, 2, 3, 6, 9, 12, 15, 18, or 24 hours of each other or within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14 days of each other or within 2, 3, 4, 5, 6, 7, 8, 9, or weeks of each other. In some cases even longer intervals are possible. While in many cases it is desirable that the two or more agents used in a combination therapy be present in within the patient's body at the same time, this need not be so.
Combination therapy can also include two or more administrations of one or more of the agents used in the combination using different sequencing of the component agents. For example, if agent X and agent Y are used in a combination, one could administer them sequentially in any combination one or more times, e.g., in the order X-Y-X, X-X-Y, Y-X-Y, Y-Y-X, X-X-Y-Y, etc. Furthermore, administration of two or more agents of the combination may precede or follow administration dosing intervals during which at least one of the combination agents is omitted from the treatment.
Additional therapeutic agents that may be administered according to the present disclosure, e.g., to treat a mastocytosis or mastocytosis tumor, include, but are not limited to, agents selected from the group consisting of: inhibitors of STATS, including but not limited to ruxolitinib, tofacitinib, or fedratinib; inhibitors of BTK including but not limited to ibrutinib, PCI 29732, acalabrutinib, or AVL-292; inhibitors of PI3 kinase including but not limited to idelalisib, dactolisib, pictilisib, LY294002, buparlisib, pilaralisib, duvelisib, PF-04691502, voxtalisib, omipalisib, gedatolisib, apitolisib, or wortmannin; inhibitors of AKT kinase including but not limited to MK-2206, perifosine, GSK690693, GSK2141795, ipatasertib, AZD5363, afuresertib, or AT7867; inhibitors of DNA methylation including but not limited to 5-azacytidine or 5-aza-2′-deoxycytidine; proteosomal inhibitors including but not limited to bortezomib, carfilzomib, MLN9708, ONX 0912; interferon-alpha (IFN-α); cladribine; and lysosomotropic agents including but not limited to chloroquine, hydroxychloroquine, or quinacrine.
In certain embodiments, the additional therapeutic agent s selected from 5-azacytidine, 5-aza-2′-deoxycytidine, and cladribine.
In particular embodiments, a subject in need thereof is treated with a combination of Compound A or a pharmaceutically acceptable salt thereof, one or two of a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, and 5-azacytidine. In certain embodiments, the MAPKAP pathway inhibitor is trametinib. In certain embodiments, the MAPKAP pathway inhibitor is binimetinib. In certain embodiments, the MAPKAP pathway inhibitor is ulixertinib. In certain embodiments, the MAPKAP pathway inhibitor is LY3009120, dabrafenib or vemurafenib.
In particular embodiments, a subject in need thereof is treated with a combination of Compound A or a pharmaceutically acceptable salt thereof, a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, and 5-aza-2′-deoxycytidine. In certain embodiments, the MAPKAP pathway inhibitor is trametinib. In certain embodiments, the MAPKAP pathway inhibitor is binimetinib. In certain embodiments, the MAPKAP pathway inhibitor is ulixertinib. In certain embodiments, the MAPKAP pathway inhibitor is LY3009120, dabrafenib or vemurafenib.
In particular embodiments, a subject in need thereof is treated with a combination of Compound A or a pharmaceutically acceptable salt thereof, MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, and cladribine. In certain embodiments, the MAPKAP pathway inhibitor is trametinib. In certain embodiments, the MAPKAP pathway inhibitor is binimetinib. In certain embodiments, the MAPKAP pathway inhibitor is ulixertinib. In certain embodiments, the MAPKAP pathway inhibitor is LY3009120, dabrafenib or vemurafenib. Additional therapeutic agents that may be administered according to the present disclosure include, but are not limited to, arsenic trioxide, cyclophosphamide, cytarabine, daunorubicin, doxorubicin, enasidenib, idarubicin, quizartinib, mitoxantrone, thioguanine, or vincristine. In particular embodiments, a subject having AML is treated with a combination of Compound A or a pharmaceutically acceptable salt thereof, and arsenic trioxide, cyclophosphamide, cytarabine, daunorubicin, doxorubicin, enasidenib, idarubicin, quizartinib, mitoxantrone, thioguanine, or vincristine.
Pharmaceutical Compositions
Aspects of the present disclosure are directed to methods of treatment involving the administration of a combination of compounds disclosed herein, or one or more pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable diluent, excipient or carrier. In particular embodiments, the methods disclosed herein involve administering a first pharmaceutical composition comprising a c-KIT inhibitor, e.g., Compound A or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent, excipient or carrier, and a second pharmaceutical composition comprising a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, and a pharmaceutically acceptable diluent, excipient or carrier. In particular embodiments, the methods disclosed herein involve administering a first pharmaceutical composition comprising Compound B or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent, excipient or carrier, and a second pharmaceutical composition comprising a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, and a pharmaceutically acceptable diluent, excipient or carrier. In particular embodiments, the methods disclosed herein involve administering a pharmaceutical composition comprising a ciKIT inhibitor, e.g., Compound A or a pharmaceutically acceptable salt thereof, a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, and a pharmaceutically acceptable diluent, excipient or carrier. In particular embodiments, the methods disclosed herein involve administering a pharmaceutical composition comprising Compound B or a pharmaceutically acceptable salt thereof, a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, and a pharmaceutically acceptable diluent, excipient or carrier.
In using the pharmaceutical compositions of the compounds described herein, pharmaceutically acceptable carriers can be either solid or liquid. Solid forms include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 95 percent active ingredient. Suitable solid carriers are known in the art, e.g., magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th Edition, (1990), Mack Publishing Co., Easton, Pa., which is hereby incorporated by reference in its entirety.
Liquid form preparations include solutions, suspensions and emulsions. For example, water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration.
Liquid, particularly injectable, compositions can, for example, be prepared by dissolution, dispersion, etc. For example, the disclosed compound is dissolved in or mixed with a pharmaceutically acceptable solvent such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form an injectable isotonic solution or suspension. Proteins such as albumin, chylomicron particles, or serum proteins can be used to solubilize the disclosed compounds.
Parental injectable administration is generally used for subcutaneous, intramuscular or intravenous injections and infusions. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions or solid forms suitable for dissolving in liquid prior to injection.
Aerosol preparations suitable for inhalation may also be used. These preparations may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g., nitrogen.
Also contemplated for use are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.
Dosage
In some embodiments where Compound A or Compound B (or pharmaceutically acceptable salts thereof) is used in combination with a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120for a treatment protocol, the two therapeutics may be administered together or in a “dual-regimen” wherein the two therapeutics are dosed and administered separately. When the Compound A or B (or pharmaceutically acceptable salts thereof) and the MAPKAP pathway inhibitor are dosed separately, the typical dosage of Compound A or Compound B (or pharmaceutically acceptable salts thereof) administered to the subject in need of the treatment is typically from about 5 mg per day to about 5000 mg per day and, in other embodiments, from about 50 mg per day to about 1000 mg per day. Other dosages may be from about 10 mmol up to about 250 mmol per day, from about 20 mmol to about 70 mmol per day or even from about 30 mmol to about 60 mmol per day. Effective dosage amounts of the disclosed compounds, when used for the indicated effects, range from about 0.5 mg to about 5000 mg of the disclosed compound as needed to treat the condition. Compositions for in vivo or in vitro use can contain about 0.5, 5, 20, 50, 75, 100, 150, 250, 500, 750, 1000, 1250, 2500, 3500, or 5000 mg of the disclosed compound, or, in a range of from one amount to another amount in the list of doses. A typical recommended daily dosage regimen for oral administration can range from about 1 mg/day to about 500 mg/day or 1 mg/day to 200 mg/day, in a single dose, or in two to four divided doses. In one embodiment, the typical daily oral dose regimen is 150 mg.
In certain embodiments, the dosage of MAPKAP pathway inhibitors is consistent with previously disclosed dosages and/or dosages approved for use by the Food and Drug Administration. In other embodiments, the dosage of the MAPKAP pathway inhibitor is less than previously approved dosages, e.g., about 20%, about 50% or about 80% of an approved dosage. In certain embodiments, the dosage of trametinib is about 0.05 mg to 20 mg orally daily, e.g., about 1 mg daily or about 2 mg daily. In certain embodiments, the dosage of cobimetinib is about 10 mg to 200 mg daily, e.g., about 30 mg or about 60 mg daily. In certain embodiments, the dosage of binimetinib is about 10 mg to about 200 mg twice daily, e.g., about 25 mg or about 45 mg twice daily. In certain embodiments, the dosage of selumetinib is about 10 mg to about 200 mg daily, or about 30 mg or about 75 mg twice daily.
The amount and frequency of administration of the compounds described herein and/or the pharmaceutically acceptable salts thereof, and other therapeutic agents, will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated.
Compounds of the present disclosure (e.g., Compound A or Compound B (and pharmaceutically acceptable salts thereof), MAPKAP pathway inhibitors, and other therapeutic agents) may be administered by any suitable route. The compounds can be administrated orally (e.g., dietary) in capsules, suspensions, tablets, pills, dragees, liquids, gels, syrups, slurries, and the like. Methods for encapsulating compositions (such as in a coating of hard gelatin or cyclodextran) are known in the art (Baker, et al., “Controlled Release of Biological Active Agents”, John Wiley and Sons, 1986, which is hereby incorporated by reference in its entirety). The compounds can be administered to the subject in conjunction with an acceptable pharmaceutical carrier as part of a pharmaceutical composition. The formulation of the pharmaceutical composition will vary according to the route of administration selected. Suitable pharmaceutical carriers may contain inert ingredients which do not interact with the compound. The carriers are biocompatible, i.e., non-toxic, non-inflammatory, non-immunogenic and devoid of other undesired reactions at the administration site.
Illustrative pharmaceutical compositions are tablets and gelatin capsules comprising a Compound described herein, e.g., Compound A or a pharmacetucially acceptable salt thereof, and a pharmaceutically acceptable carrier, such as a) a diluent, e.g., purified water, triglyceride oils, such as hydrogenated or partially hydrogenated vegetable oil, or mixtures thereof, corn oil, olive oil, sunflower oil, safflower oil, fish oils, such as EPA or DHA, or their esters or triglycerides or mixtures thereof, omega-3 fatty acids or derivatives thereof, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, sodium, saccharin, glucose and/or glycine; b) a lubricant, e.g., silica, talcum, stearic acid, its magnesium or calcium salt, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and/or polyethylene glycol; for tablets also; c) a binder, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, magnesium carbonate, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, waxes and/or polyvinylpyrrolidone, if desired; d) a disintegrant, e.g., starches, agar, methyl cellulose, bentonite, xanthan gum, algic acid or its sodium salt, or effervescent mixtures; e) absorbent, colorant, flavorant and sweetener; f) an emulsifier or dispersing agent, such as Tween 80, Labrasol, HPMC, DOSS, caproyl 909, labrafac, labrafil, peceol, transcutol, capmul MCM, capmul PG-12, captex 355, gelucire, vitamin E TGPS or other acceptable emulsifier; and/or g) an agent that enhances absorption of the compound such as cyclodextrin, hydroxypropyl-cyclodextrin, PEG400, PEG200.
If formulated as a fixed dose, such combination products employ the compounds described herein within the dosage range described herein, or as known to those skilled in the art.
Since the compounds described herein (e.g., Compounds A and B and MAPKAP pathway inhibitors) are intended for use in pharmaceutical compositions a skilled artisan will understand that they can be provided in substantially pure forms for example, at least 60% pure, at least 75% pure, at least 85% pure, and at least 98% pure (w/w). The pharmaceutical preparation may be in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of compounds A or B, e.g., an effective amount to achieve the desired purpose as described herein.
It has been found that treatment with a combination of either Compound A or a pharmaceutically acceptable salt thereof in combination with a MAPKAP pathway inhibitor unexpectedly and synergistically induce apoptosis of mutant c-KIT-driven mast cells causative of systemic mastocytosis. In addition, this combination therapy inhibits proliferation of mastocytosis cells. Furthermore, the combination therapy disclosed herein appeared to have a cytotoxic effect on mastocytosis, as opposed to merely a cytostatic effect as determined by combination treatment-induced in caspase activation. Characterization of this unexpected finding was undertaken in biochemical assays and cellular assays, including those described herein.
The disclosure is thus further illustrated by the following examples, which are not to be construed as limiting this disclosure in scope or spirit to the specific procedures herein described. It is to be understood that the examples are provided to illustrate certain embodiments and that no limitation to the scope of the disclosure is intended thereby. It is to be further understood that resort may be had to various other embodiments, modifications, and equivalents thereof which may suggest themselves to those skilled in the art without departing from the spirit of the present disclosure and/or scope of the appended claims.
A study was performed that demonstrates that treatment with Compound A or Compound B inhibited cell proliferation of mutant KIT HMC1.1 KIT V560G and HMC1.2 KIT V560G/D816V mast cell lines. Assays were conducted in 96 well plates with 10,000 cells seeded per well. The cells were treated with vehicle control, Compound A, or Compound B thereof at varying concentrations, allowed to grow for 72 hours, and then cell proliferation was assessed.
A study was performed to demonstrate that combination treatment with Compound A and the MEK inhibitor trametinib induced apoptosis in the HMC1.2 KIT V560G/D816V mastocytosis cell line. Assays were conducted in 96 well plates with 10,000 cells seeded per well. Cells were treated with vehicle control, Compound A, trametinib, or combinations thereof at varying concentrations, and the cells were allowed to grow for 24 hours. Apoptosis was assessed by measuring caspase 3/7 activity.
A study was also performed to demonstrate that combination treatment with Compound B and trametinib induced apoptosis in the HMC1.2 KIT V560G/D816V mastocytosis cell line. Assays were conducted as explained in example 2. Apoptosis was assessed by measuring caspase 3/7 activity.
Combination treatment with Compound A and binimetinib also induced apoptosis in the HMC1.2 KIT V560G/D816V mastocytosis cell line. Assays were conducted as explained in example 2. Apoptosis was assessed by measuring caspase 3/7 activity.
Combination treatment of Compound B and the ERK inhibitor ulixertinib can be evaluated for induction of apoptosis in HMC1.2 KIT V560G/D816V mast cells. A matrix for synergy chart based on the combination index (CI) method can be generated as described by Chou and Talalay (1984) and the computer software of Chou and Martin (2005). Combination treatments with Compound B and ulixertinib can be used to show synergy for inducing apoptosis of HMC1.2 KIT V560G/D816V cells. A Combination Index Plot of the CI can be used to demonstrate synergy for combination of Compound B and ulixertinib for inducing apoptosis of HMC1.2 KIT V560G/D816V mast cells.
Combination treatment of Compound A and the ERK inhibitor SCH772984 can be evaluated for induction of apoptosis in HMC1.2 KIT V560G/D816V mast cells. A matrix for synergy chart based on the combination index (CI) method can be generated as described by Chou and Talalay (1984) and the computer software of Chou and Martin (2005). Combination treatments with Compound A and SCH772984 can be used to show synergy for inducing apoptosis of HMC1.2 KIT V560G/D816V cells. A Combination Index Plot of the CI can be used to demonstrate synergy for combination of Compound A and SCH772984 for inducing apoptosis of HMC1.2 KIT V560G/D816V mast cells.
Combination treatment of Compound B and the ERK inhibitor SCH772984 can be evaluated for induction of apoptosis in HMC1.2 KIT V560G/D816V mast cells. A matrix for synergy chart based on the combination index (CI) method can be generated as described by Chou and Talalay (1984) and the computer software of Chou and Martin (2005). Combination treatments with Compound A and SCH772984 can be used to show synergy for inducing apoptosis of HMC1.2 KIT V560G/D816V cells. A Combination Index Plot of the CI can be used to demonstrate synergy for combination of Compound B and SCH772984 for inducing apoptosis of HMC1.2 KIT V560G/D816V mast cells.
Combination treatment of Compound A and the RAF inhibitor LY3009120 can be evaluated for induction of apoptosis in HMC1.2 KIT V560G/D816V mast cells. A matrix for synergy chart based on the combination index (CI) method can be generated as described by Chou and Talalay (1984) and the computer software of Chou and Martin (2005). Combination treatments with Compound A and LY3009120 can be used to show synergy for inducing apoptosis of HMC1.2 KIT V560G/D816V cells. A Combination Index Plot of the CI can be used to demonstrate strong synergy for combination of Compound A and LY3009120 for inducing apoptosis of HMC1.2 KIT V560G/D816V mast cells.
Combination treatment of Compound B and the RAF inhibitor LY3009120 can be evaluated for induction of apoptosis in HMC1.2 KIT V560G/D816V mast cells. A matrix for synergy chart based on the combination index (CI) method can be generated as described by Chou and Talalay (1984) and the computer software of Chou and Martin (2005). Combination treatments with Compound B and LY3009120 can be used to show synergy for inducing apoptosis of HMC1.2 KIT V560G/D816V cells. A Combination Index Plot of the CI can be used to demonstrate synergy for combination of Compound B and LY3009120 for inducing apoptosis of HMC1.2 KIT V560G/D816V mast cells.
A study was performed to demonstrate that combination treatment with Compound A and the MEK inhibitor trametinib leads to decreased colony out growth of HMC1.2, compared to treatment with either single agent. 10,000 HMC1.2 cells were grown in soft agar and incubated with various concentrations of Compound A, trametinib, or a combination of Compound A and trametinib for 10 days. Drug treatments were removed and colony outgrowth of viable cells was monitored after 5 additional days.
A study was also performed with Compound B and the MEK inhibitor trametinib to evaluate a decrease in colony outgrowth in HMC1.2 cells as described in Example 14.
Combination treatment of Compound A and ulixertinib can be evaluated for inhibition of colony outgrowth of HMC1.2 KIT D816V mast cell line according to the method of Example 14.
Combination treatment of Compound B and ulixertinib can be evaluated for inhibition of colony outgrowth of HMC1.2 KIT D816V mast cell line according to the method of Example 14.
Combination treatment of Compound A and the RAF inhibitor LY3009120 can be evaluated for inhibition of colony outgrowth of HMC1.2 KIT D816V mast cell line according to the method of Example 14.
Combination treatment of Compound B and the RAF inhibitor LY3009120 can be evaluated for inhibition of colony outgrowth of HMC1.2 KIT D816V mast cell line according to the method of Example 14.
A study was performed to demonstrate that combination treatment with Compound A and trametinib induced apoptosis in mutant N-ras G12D transfected HMC1.2 V560G/D816V cells. Assays were conducted in 96 well plates with 10,000 cells seeded per well. Cells were treated with vehicle control, Compound A, trametinib, or combinations thereof at varying concentrations, and the cells were allowed to grow for 24 and 48 hours. Apoptosis was assessed by measuring caspase 3/7 activity.
A study was performed to demonstrate that combination treatment with Compound A and trametinib leads to decreased colony out growth of HMC1.2 transfected with empty vector (EV) or transfected with N-ras G12D, compared to treatment with either single agent. HMC1.2 cells were incubated with various concentrations of Compound A, trametinib, or a combination of Compound A and trametinib for 10 days. Drug treatments were removed and colony outgrowth of viable cells was monitored after 5 or 13 additional days.
A study was performed to demonstrate that combination treatment with Compound A and cobimetinib leads to decreased colony out growth of HMC1.2 transfected with empty vector (EV) or transfected with N-ras G12D, compared to treatment with either single agent. HMC1.2 cells were incubated with various concentrations of Compound A, cobimetinib, or a combination of Compound A and cobimetinib for 10 days. Drug treatments were removed and colony outgrowth of viable cells was monitored after 5 or 10 additional days.
Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific embodiments described specifically in this disclosure. Such equivalents are intended to be encompassed in the scope of the following claims.
This application is a continuation of International Application Number PCT/US2019/016161 filed Jan. 31, 2019, which claims priority to U.S. Ser. No. 62/624,453 filed Jan. 31, 2018, the contents of which are incorporated herein by reference in their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3528980 | Islip | Sep 1970 | A |
| 3818024 | Krenzer | Jun 1974 | A |
| 3939122 | Merten et al. | Feb 1976 | A |
| 3949002 | Feasey et al. | Apr 1976 | A |
| 4093624 | Revankar et al. | Jun 1978 | A |
| 4296237 | Cragoe, Jr. et al. | Oct 1981 | A |
| 4366189 | Burdeska et al. | Dec 1982 | A |
| 4432992 | Craqoe, Jr. et al. | Feb 1984 | A |
| 4525450 | Toh et al. | Jun 1985 | A |
| 4816454 | Zoller et al. | Mar 1989 | A |
| 5103014 | Musser et al. | Apr 1992 | A |
| 5162360 | Creswell et al. | Nov 1992 | A |
| 5189045 | Peglion et al. | Feb 1993 | A |
| 5319099 | Kamata et al. | Jun 1994 | A |
| 5494925 | Court et al. | Feb 1996 | A |
| 5514691 | Chan et al. | May 1996 | A |
| 5614532 | Carling et al. | Mar 1997 | A |
| 5621010 | Sueda | Apr 1997 | A |
| 5658924 | Matsuura et al. | Aug 1997 | A |
| 5721231 | Moriwaki et al. | Feb 1998 | A |
| 5811456 | Seman et al. | Sep 1998 | A |
| 6020357 | Pinto et al. | Feb 2000 | A |
| 6028085 | Bromidge | Feb 2000 | A |
| 6080763 | Regan et al. | Jun 2000 | A |
| 6123964 | Asgharnejad et al. | Sep 2000 | A |
| 6147088 | Goulet et al. | Nov 2000 | A |
| 6197599 | Chin et al. | Mar 2001 | B1 |
| 6235786 | Dai et al. | May 2001 | B1 |
| 6294573 | Curtin et al. | Sep 2001 | B1 |
| 6319921 | Cirillo et al. | Nov 2001 | B1 |
| 6410254 | Finer et al. | Jun 2002 | B1 |
| 6500628 | Robison | Dec 2002 | B1 |
| 6525046 | Cirillo et al. | Feb 2003 | B1 |
| 6645990 | Askew et al. | Nov 2003 | B2 |
| 6763607 | Beyerinck et al. | Jul 2004 | B2 |
| 6916924 | Tan et al. | Jul 2005 | B2 |
| 6973741 | Beyerinck et al. | Dec 2005 | B2 |
| 7071199 | Hirst et al. | Jul 2006 | B1 |
| 7135550 | Come et al. | Nov 2006 | B2 |
| 7144911 | Flynn et al. | Dec 2006 | B2 |
| 7202257 | Flynn et al. | Apr 2007 | B2 |
| 7211575 | Moss et al. | May 2007 | B2 |
| 7279576 | Flynn et al. | Oct 2007 | B2 |
| 7342037 | Flynn et al. | Mar 2008 | B2 |
| 7531566 | Flynn et al. | May 2009 | B2 |
| 7666895 | Flynn et al. | Feb 2010 | B2 |
| 7737283 | Flynn et al. | Jun 2010 | B2 |
| 7790756 | Flynn et al. | Sep 2010 | B2 |
| 7897762 | Flynn et al. | Mar 2011 | B2 |
| 8143293 | Flynn et al. | Mar 2012 | B2 |
| 8163756 | Flynn et al. | Apr 2012 | B2 |
| 8188113 | Flynn et al. | May 2012 | B2 |
| 8278331 | Flynn et al. | Oct 2012 | B2 |
| 8343550 | Beyerinck et al. | Jan 2013 | B2 |
| 8461179 | Flynn et al. | Jun 2013 | B1 |
| 8486951 | Flynn et al. | Jul 2013 | B2 |
| 8569319 | Flynn et al. | Oct 2013 | B2 |
| 8586565 | Flynn et al. | Nov 2013 | B2 |
| 8637672 | Flynn et al. | Jan 2014 | B2 |
| 8669289 | Li | Mar 2014 | B2 |
| 8741911 | Allgeier et al. | Jun 2014 | B2 |
| 8828443 | Beyerinck et al. | Sep 2014 | B2 |
| 8921565 | Flynn et al. | Dec 2014 | B2 |
| 8940756 | Flynn et al. | Jan 2015 | B2 |
| 9012635 | Flynn et al. | Apr 2015 | B2 |
| 9133183 | Flynn et al. | Sep 2015 | B2 |
| 9181223 | Kaufman et al. | Nov 2015 | B2 |
| 9187474 | Flynn et al. | Nov 2015 | B2 |
| 9193719 | Flynn et al. | Nov 2015 | B2 |
| 9248584 | Friesen et al. | Feb 2016 | B2 |
| 9265731 | Ray et al. | Feb 2016 | B2 |
| 9309224 | Flynn et al. | Apr 2016 | B2 |
| 9334267 | Flynn et al. | May 2016 | B2 |
| 9339467 | Beyerinck et al. | May 2016 | B2 |
| 9382228 | Flynn et al. | Jul 2016 | B2 |
| 9387202 | Flynn et al. | Jul 2016 | B2 |
| 9457019 | Flynn et al. | Oct 2016 | B2 |
| 9545407 | Shu et al. | Jan 2017 | B2 |
| 9724664 | Friesen et al. | Aug 2017 | B2 |
| 10300443 | Friesen et al. | May 2019 | B2 |
| 10383941 | Beyerinck et al. | Aug 2019 | B2 |
| 10675602 | Friesen et al. | Jun 2020 | B2 |
| 10966966 | Soto et al. | Apr 2021 | B2 |
| 11103507 | Flynn et al. | Aug 2021 | B2 |
| RE48731 | Flynn et al. | Sep 2021 | E |
| 11185535 | Kaufman et al. | Nov 2021 | B2 |
| 11266635 | Soto et al. | Mar 2022 | B2 |
| 11344536 | Soto et al. | May 2022 | B1 |
| 11395818 | Kaufman et al. | Jul 2022 | B2 |
| 11426390 | Soto et al. | Aug 2022 | B2 |
| 11433056 | Soto et al. | Sep 2022 | B1 |
| 11518758 | Flynn et al. | Dec 2022 | B2 |
| 11529336 | Soto et al. | Dec 2022 | B2 |
| 11530206 | Flynn et al. | Dec 2022 | B2 |
| 11534432 | Soto et al. | Dec 2022 | B2 |
| 11576903 | Kaufman et al. | Feb 2023 | B2 |
| 11576904 | Soto et al. | Feb 2023 | B2 |
| 11590134 | Flynn et al. | Feb 2023 | B2 |
| 11612591 | Kaufman et al. | Mar 2023 | B2 |
| 11679110 | Flynn et al. | Jun 2023 | B2 |
| 11779572 | Wang et al. | Oct 2023 | B1 |
| 11793795 | Kaufman et al. | Oct 2023 | B2 |
| 11801237 | Kaufman et al. | Oct 2023 | B2 |
| 11813251 | Soto et al. | Nov 2023 | B2 |
| 20020058678 | Cirillo et al. | May 2002 | A1 |
| 20020077486 | Scarborough et al. | Jun 2002 | A1 |
| 20020165394 | Dumas et al. | Nov 2002 | A1 |
| 20020193405 | Askew | Dec 2002 | A1 |
| 20030060455 | Moss et al. | Mar 2003 | A1 |
| 20030105139 | Gaster et al. | Jun 2003 | A1 |
| 20030144278 | Riedl et al. | Jul 2003 | A1 |
| 20030181442 | Riedl et al. | Sep 2003 | A1 |
| 20030207870 | Dumas et al. | Nov 2003 | A1 |
| 20030216396 | Dumas et al. | Nov 2003 | A1 |
| 20030232865 | Cirillo et al. | Dec 2003 | A1 |
| 20040043388 | Come et al. | Mar 2004 | A1 |
| 20040067938 | Zhang et al. | Apr 2004 | A1 |
| 20040102636 | Miller et al. | May 2004 | A1 |
| 20040157827 | Pevarello et al. | Aug 2004 | A1 |
| 20040167224 | Ozaki et al. | Aug 2004 | A1 |
| 20040171075 | Flynn et al. | Sep 2004 | A1 |
| 20040180906 | Flynn et al. | Sep 2004 | A1 |
| 20040229937 | Dumas et al. | Nov 2004 | A1 |
| 20050014753 | Ding et al. | Jan 2005 | A1 |
| 20050148605 | Grotzfeld et al. | Jul 2005 | A1 |
| 20050165024 | Milanov et al. | Jul 2005 | A1 |
| 20050165031 | Grotzfeld et al. | Jul 2005 | A1 |
| 20050165074 | Grotzfeld et al. | Jul 2005 | A1 |
| 20050171171 | Mehta et al. | Aug 2005 | A1 |
| 20050171172 | Lai et al. | Aug 2005 | A1 |
| 20050192314 | Mehta et al. | Sep 2005 | A1 |
| 20050197371 | Milanov et al. | Sep 2005 | A1 |
| 20050256174 | Wood et al. | Nov 2005 | A1 |
| 20050261315 | Mehta et al. | Nov 2005 | A1 |
| 20050267182 | Milanov et al. | Dec 2005 | A1 |
| 20050288286 | Flynn et al. | Dec 2005 | A1 |
| 20060229337 | Brittelli et al. | Oct 2006 | A1 |
| 20060247186 | Carter et al. | Nov 2006 | A1 |
| 20070037794 | Ungashe et al. | Feb 2007 | A1 |
| 20070078121 | Flynn et al. | Apr 2007 | A1 |
| 20070155764 | Lang et al. | Jul 2007 | A1 |
| 20070179130 | Bannen | Aug 2007 | A1 |
| 20070191336 | Flynn et al. | Aug 2007 | A1 |
| 20070244120 | Dumas et al. | Oct 2007 | A1 |
| 20070293685 | Fritch et al. | Dec 2007 | A1 |
| 20080009527 | Dumas et al. | Jan 2008 | A1 |
| 20080045531 | Flynn et al. | Feb 2008 | A1 |
| 20080045706 | Flynn et al. | Feb 2008 | A1 |
| 20080064717 | Iyengar et al. | Mar 2008 | A1 |
| 20080090856 | Flynn et al. | Apr 2008 | A1 |
| 20080113967 | Flynn et al. | May 2008 | A1 |
| 20080114006 | Flynn et al. | May 2008 | A1 |
| 20080132506 | Flynn et al. | Jun 2008 | A1 |
| 20080176846 | Chianelli et al. | Jul 2008 | A1 |
| 20080187978 | Flynn et al. | Aug 2008 | A1 |
| 20080194836 | Gharbaoui et al. | Aug 2008 | A1 |
| 20080200530 | Unett et al. | Aug 2008 | A1 |
| 20080207699 | Hoelzemann et al. | Aug 2008 | A1 |
| 20080214545 | Lee et al. | Sep 2008 | A1 |
| 20080220497 | Flynn et al. | Sep 2008 | A1 |
| 20080221192 | Wan et al. | Sep 2008 | A1 |
| 20080248487 | Flynn et al. | Oct 2008 | A1 |
| 20080248548 | Flynn et al. | Oct 2008 | A1 |
| 20080300281 | Dumas et al. | Dec 2008 | A1 |
| 20090069310 | Flynn et al. | Mar 2009 | A1 |
| 20090075986 | Flynn et al. | Mar 2009 | A1 |
| 20090093526 | Miller et al. | Apr 2009 | A1 |
| 20090099190 | Flynn et al. | Apr 2009 | A1 |
| 20090105230 | Flynn et al. | Apr 2009 | A1 |
| 20090124633 | Jonczyk et al. | May 2009 | A1 |
| 20090137021 | Flynn et al. | May 2009 | A1 |
| 20090192307 | Michelotti et al. | Jul 2009 | A1 |
| 20090215799 | Stieber et al. | Aug 2009 | A1 |
| 20090281089 | Gunzner et al. | Nov 2009 | A1 |
| 20090312349 | Flynn et al. | Dec 2009 | A1 |
| 20090325945 | Niculescu-Duvaz et al. | Dec 2009 | A1 |
| 20100075971 | Dumas et al. | Mar 2010 | A1 |
| 20100160292 | Whitney et al. | Jun 2010 | A1 |
| 20100209420 | Lamb et al. | Aug 2010 | A1 |
| 20100286215 | Pelcman et al. | Nov 2010 | A1 |
| 20100298290 | Anand et al. | Nov 2010 | A1 |
| 20110077240 | Mannion et al. | Mar 2011 | A1 |
| 20110092461 | Gunzner et al. | Apr 2011 | A1 |
| 20110098293 | Mannion et al. | Apr 2011 | A1 |
| 20110112193 | Nilsson et al. | May 2011 | A1 |
| 20110124640 | Liu et al. | May 2011 | A1 |
| 20110136760 | Flynn et al. | Jun 2011 | A1 |
| 20110136809 | Lee et al. | Jun 2011 | A1 |
| 20110183997 | Chianelli et al. | Jul 2011 | A1 |
| 20110195110 | Smith et al. | Aug 2011 | A1 |
| 20110237563 | Costantini | Sep 2011 | A1 |
| 20120094980 | Gunzner et al. | Apr 2012 | A1 |
| 20120114605 | Li | May 2012 | A1 |
| 20120214808 | Bloxham et al. | Aug 2012 | A1 |
| 20120225057 | Flynn et al. | Sep 2012 | A1 |
| 20120270878 | Miller et al. | Oct 2012 | A1 |
| 20120289540 | Flynn et al. | Nov 2012 | A1 |
| 20130071403 | Rolland et al. | Mar 2013 | A1 |
| 20130225581 | Furuta et al. | Aug 2013 | A1 |
| 20130296326 | Pollock | Nov 2013 | A1 |
| 20140088075 | Flynn et al. | Mar 2014 | A1 |
| 20140107100 | Rice et al. | Apr 2014 | A1 |
| 20140147415 | Moussy et al. | May 2014 | A1 |
| 20140179632 | Mannion et al. | Jun 2014 | A1 |
| 20140296248 | Bernards et al. | Oct 2014 | A1 |
| 20140296267 | Fry et al. | Oct 2014 | A1 |
| 20140336210 | Christopher et al. | Nov 2014 | A1 |
| 20150031648 | Le Tiran et al. | Jan 2015 | A1 |
| 20150073141 | Teegarden et al. | Mar 2015 | A1 |
| 20150105550 | Gunzner et al. | Apr 2015 | A1 |
| 20150111879 | Gunzner et al. | Apr 2015 | A1 |
| 20150133462 | Singh et al. | May 2015 | A1 |
| 20150218652 | Doebele et al. | Aug 2015 | A1 |
| 20150225369 | Wucherer-Plietker et al. | Aug 2015 | A1 |
| 20150246033 | Flynn et al. | Sep 2015 | A1 |
| 20150275306 | Bernards et al. | Oct 2015 | A1 |
| 20150320759 | Flynn et al. | Nov 2015 | A1 |
| 20160009709 | Cheve et al. | Jan 2016 | A1 |
| 20160045532 | Roberts et al. | Feb 2016 | A1 |
| 20160152569 | Gunzner-Toste et al. | Jun 2016 | A1 |
| 20160166679 | Low et al. | Jun 2016 | A1 |
| 20160222012 | Ruan | Aug 2016 | A1 |
| 20160243150 | Wood et al. | Aug 2016 | A1 |
| 20160289663 | Kiyokawa et al. | Oct 2016 | A1 |
| 20160374990 | Teegarden et al. | Dec 2016 | A1 |
| 20170015627 | Gunzner-Toste et al. | Jan 2017 | A1 |
| 20170121321 | Crews et al. | May 2017 | A1 |
| 20170174750 | Lim et al. | Jun 2017 | A1 |
| 20170349880 | Doucey et al. | Dec 2017 | A1 |
| 20170360791 | Joshi-Hangal et al. | Dec 2017 | A1 |
| 20180000771 | Inoue et al. | Jan 2018 | A1 |
| 20180071302 | Abella et al. | Mar 2018 | A1 |
| 20180071303 | Abella et al. | Mar 2018 | A1 |
| 20190091217 | Flynn et al. | Mar 2019 | A1 |
| 20200129489 | Flynn et al. | Apr 2020 | A1 |
| 20200253973 | Flynn et al. | Aug 2020 | A1 |
| 20200352920 | Flynn et al. | Nov 2020 | A1 |
| 20200354346 | Flynn et al. | Nov 2020 | A1 |
| 20200354352 | Flynn et al. | Nov 2020 | A1 |
| 20210015801 | Flynn et al. | Jan 2021 | A1 |
| Number | Date | Country |
|---|---|---|
| 101528744 | Sep 2009 | CN |
| 101553232 | Oct 2009 | CN |
| 102731385 | Oct 2012 | CN |
| 105461699 | Apr 2016 | CN |
| 106573002 | Apr 2017 | CN |
| 106822128 | Jun 2017 | CN |
| 108379591 | Aug 2018 | CN |
| 111328283 | Jun 2020 | CN |
| 114902895 | Aug 2022 | CN |
| 1115350 | Oct 1961 | DE |
| 4343831 | Jun 1995 | DE |
| 0021228 | Jan 1981 | EP |
| 0025232 | Mar 1981 | EP |
| 0154190 | Sep 1985 | EP |
| 0661276 | Jul 1995 | EP |
| 0692483 | Nov 1995 | EP |
| 0739884 | Oct 1996 | EP |
| 0867435 | Sep 1998 | EP |
| 0927555 | Jul 1999 | EP |
| 928790 | Jul 1999 | EP |
| 0956855 | Nov 1999 | EP |
| 1281399 | Feb 2003 | EP |
| 2858646 | Apr 2015 | EP |
| 2827900 | Mar 2018 | EP |
| 2337554 | Aug 1977 | FR |
| 2396549 | Feb 1979 | FR |
| 971307 | Sep 1964 | GB |
| 1410279 | Oct 1975 | GB |
| 2220206 | Jan 1990 | GB |
| 59-177557 | Aug 1984 | JP |
| 9221476 | Aug 1997 | JP |
| 2000275886 | Oct 2000 | JP |
| 20012687 | Jan 2001 | JP |
| 2010-506948 | Mar 2010 | JP |
| 2015-520186 | Jul 2015 | JP |
| 2015-532296 | Nov 2015 | JP |
| 59-15247 | May 2016 | JP |
| 20130065368 | Jun 2013 | KR |
| 199119708 | Dec 1991 | WO |
| 199208693 | May 1992 | WO |
| 199418176 | Aug 1994 | WO |
| 199421617 | Sep 1994 | WO |
| 199424095 | Oct 1994 | WO |
| 1995006044 | Mar 1995 | WO |
| 199515954 | Jun 1995 | WO |
| 199529902 | Nov 1995 | WO |
| 199534540 | Dec 1995 | WO |
| 199616046 | May 1996 | WO |
| 199619477 | Jun 1996 | WO |
| 1996023783 | Aug 1996 | WO |
| 199734900 | Sep 1997 | WO |
| 1997037989 | Oct 1997 | WO |
| 199740028 | Oct 1997 | WO |
| 1997045400 | Dec 1997 | WO |
| 199822103 | May 1998 | WO |
| 199852558 | Nov 1998 | WO |
| 199915164 | Apr 1999 | WO |
| 199923091 | May 1999 | WO |
| 199923093 | May 1999 | WO |
| 199932106 | Jul 1999 | WO |
| 199932110 | Jul 1999 | WO |
| 199932111 | Jul 1999 | WO |
| 199932455 | Jul 1999 | WO |
| 199937622 | Jul 1999 | WO |
| 199959959 | Nov 1999 | WO |
| 200006550 | Feb 2000 | WO |
| 200007980 | Feb 2000 | WO |
| 200018738 | Apr 2000 | WO |
| 200021927 | Apr 2000 | WO |
| 200041698 | Jul 2000 | WO |
| 2000042012 | Jul 2000 | WO |
| 200043384 | Jul 2000 | WO |
| 200055139 | Sep 2000 | WO |
| 200059506 | Oct 2000 | WO |
| 2000071515 | Nov 2000 | WO |
| 200112621 | Feb 2001 | WO |
| 200114372 | Mar 2001 | WO |
| 200174771 | Oct 2001 | WO |
| 200196298 | Dec 2001 | WO |
| 200200647 | Jan 2002 | WO |
| 2002014291 | Feb 2002 | WO |
| 2002014311 | Feb 2002 | WO |
| 2002026712 | Apr 2002 | WO |
| 2002028835 | Apr 2002 | WO |
| 2002034727 | May 2002 | WO |
| 2002060869 | Aug 2002 | WO |
| 2002060876 | Aug 2002 | WO |
| 2002062763 | Aug 2002 | WO |
| 2002070662 | Sep 2002 | WO |
| 2003005999 | Jan 2003 | WO |
| WO-03002114 | Jan 2003 | WO |
| 2003047579 | Jun 2003 | WO |
| 2003053368 | Jul 2003 | WO |
| 2003059373 | Jul 2003 | WO |
| 2003068223 | Aug 2003 | WO |
| 2003068229 | Aug 2003 | WO |
| 2003072577 | Sep 2003 | WO |
| 2003084539 | Oct 2003 | WO |
| 2004004720 | Jan 2004 | WO |
| 2004056783 | Jul 2004 | WO |
| 2004060305 | Jul 2004 | WO |
| 2004060306 | Jul 2004 | WO |
| 2004061084 | Jul 2004 | WO |
| 2004078128 | Sep 2004 | WO |
| 2004078746 | Sep 2004 | WO |
| 2004113352 | Dec 2004 | WO |
| 2005002673 | Jan 2005 | WO |
| 2005012254 | Feb 2005 | WO |
| 2005024755 | Mar 2005 | WO |
| 2005034869 | Apr 2005 | WO |
| 2005048948 | Jun 2005 | WO |
| 2005103011 | Nov 2005 | WO |
| 2005110994 | Nov 2005 | WO |
| 2006014290 | Feb 2006 | WO |
| 2006014325 | Feb 2006 | WO |
| 2006018662 | Feb 2006 | WO |
| 2006028958 | Mar 2006 | WO |
| 2006039718 | Apr 2006 | WO |
| 2006040056 | Apr 2006 | WO |
| 2006046552 | May 2006 | WO |
| 2006052936 | May 2006 | WO |
| 2006062984 | Jun 2006 | WO |
| 2006071940 | Jul 2006 | WO |
| 2006072589 | Jul 2006 | WO |
| 2006078610 | Jul 2006 | WO |
| 2006081034 | Aug 2006 | WO |
| 2006081335 | Aug 2006 | WO |
| 2006099075 | Sep 2006 | WO |
| 2006105844 | Oct 2006 | WO |
| 2007008917 | Jan 2007 | WO |
| 2007042321 | Apr 2007 | WO |
| 2007064872 | Jun 2007 | WO |
| 2007076473 | Jul 2007 | WO |
| 2007081690 | Jul 2007 | WO |
| 2007115670 | Oct 2007 | WO |
| 2007125330 | Nov 2007 | WO |
| 2007136465 | Nov 2007 | WO |
| 2007137107 | Nov 2007 | WO |
| 2008033858 | Mar 2008 | WO |
| 2008033999 | Mar 2008 | WO |
| 2008034008 | Mar 2008 | WO |
| 2008046003 | Apr 2008 | WO |
| 2008051757 | May 2008 | WO |
| 2008131227 | Oct 2008 | WO |
| 2008131253 | Oct 2008 | WO |
| 2008140895 | Nov 2008 | WO |
| 2009030887 | Mar 2009 | WO |
| 2009076454 | Jun 2009 | WO |
| 2009109035 | Sep 2009 | WO |
| 2009126863 | Oct 2009 | WO |
| 2009127822 | Oct 2009 | WO |
| 2009138758 | Nov 2009 | WO |
| 2010011837 | Jan 2010 | WO |
| 2010051373 | May 2010 | WO |
| 2010124283 | Oct 2010 | WO |
| 2010135524 | Nov 2010 | WO |
| 2011067306 | Jun 2011 | WO |
| 2011123788 | Oct 2011 | WO |
| 2011137342 | Nov 2011 | WO |
| 2011139891 | Nov 2011 | WO |
| 2011150198 | Dec 2011 | WO |
| 2012008563 | Jan 2012 | WO |
| 2012019015 | Feb 2012 | WO |
| 2012035131 | Mar 2012 | WO |
| 2012071519 | May 2012 | WO |
| 2012097021 | Jul 2012 | WO |
| 2012138783 | Oct 2012 | WO |
| 2013036232 | Mar 2013 | WO |
| 2013043569 | Mar 2013 | WO |
| 2013066440 | May 2013 | WO |
| 2013078295 | May 2013 | WO |
| 2013134243 | Sep 2013 | WO |
| 2013134252 | Sep 2013 | WO |
| 2013134298 | Sep 2013 | WO |
| 2013177420 | Nov 2013 | WO |
| 2013184119 | Dec 2013 | WO |
| 2014015056 | Jan 2014 | WO |
| 2014032755 | Mar 2014 | WO |
| 2014036387 | Mar 2014 | WO |
| 2014037480 | Mar 2014 | WO |
| 2014040242 | Mar 2014 | WO |
| 2014040549 | Mar 2014 | WO |
| 2014058317 | Apr 2014 | WO |
| 2014102376 | Jul 2014 | WO |
| 2014102377 | Jul 2014 | WO |
| 2014139458 | Sep 2014 | WO |
| 2014145004 | Sep 2014 | WO |
| 2014145015 | Sep 2014 | WO |
| 2014145023 | Sep 2014 | WO |
| 2014145025 | Sep 2014 | WO |
| 2014145028 | Sep 2014 | WO |
| 2014145029 | Sep 2014 | WO |
| 2014160183 | Oct 2014 | WO |
| 2014182643 | Nov 2014 | WO |
| 2015011399 | Jan 2015 | WO |
| WO-2015051252 | Apr 2015 | WO |
| 2015069217 | May 2015 | WO |
| 2015069266 | May 2015 | WO |
| 2015076213 | May 2015 | WO |
| 2015092423 | Jun 2015 | WO |
| 2015106292 | Jul 2015 | WO |
| 2015106294 | Jul 2015 | WO |
| 2015148620 | Oct 2015 | WO |
| 2015184443 | Dec 2015 | WO |
| WO-2016025621 | Feb 2016 | WO |
| 2016061228 | Apr 2016 | WO |
| 2016061231 | Apr 2016 | WO |
| 2016096903 | Jun 2016 | WO |
| 2016103223 | Jun 2016 | WO |
| 2016114322 | Jul 2016 | WO |
| 2016135046 | Sep 2016 | WO |
| 2016154524 | Sep 2016 | WO |
| 2016196141 | Dec 2016 | WO |
| 2017013160 | Jan 2017 | WO |
| 2017042944 | Mar 2017 | WO |
| WO-2017033113 | Mar 2017 | WO |
| 2017079267 | May 2017 | WO |
| 2017117182 | Jul 2017 | WO |
| 2017146794 | Aug 2017 | WO |
| 2017146795 | Aug 2017 | WO |
| 2017214514 | Dec 2017 | WO |
| 2018005737 | Jan 2018 | WO |
| 2018052053 | Mar 2018 | WO |
| 2018053189 | Mar 2018 | WO |
| 2018106595 | Jun 2018 | WO |
| 2018195450 | Oct 2018 | WO |
| 2018222173 | Dec 2018 | WO |
| 2018222644 | Dec 2018 | WO |
| WO-2019084462 | May 2019 | WO |
| WO-2019152711 | Aug 2019 | WO |
| WO-2020185812 | Sep 2020 | WO |
| WO-2021030405 | Feb 2021 | WO |
| Entry |
|---|
| “A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies,” ClinicalTrials.gov, Jan. 12, 2018, pp. 1-11. Retrieved from the Internet: URL: <https://clinicaltrials.gov/ct2/show/NC>. |
| “NHLBI LBC Computational Biophysics Scetion”, CHARMM Documentation Index, http://www.lobos.nih.gov/Charmm/chmdoc.html, printed Mar. 4, 2005. |
| “Trilateral Project WM4—Comparative Studies in New Technologies: Report on Comparative Study on Protein 3—Dimensional Structure Related Claims—Annex 3: Comments of the USPTO”, Vienna, Austria, Nov. 4-8, pp. 58-79 (2002). |
| Additions and Corrections, Journal of Medicinal Chemistry, 32(12):2583 (1989). |
| Aklilu, et al., “Increased PTHRP Production by a Tyrosine Kinase Oncogene, Tpr-Met: Rose of the Ras Signaling Pathway”, The American Physiological Society, pp. E277-E283 (1996). |
| Albericio, et al., “Synthesis of a Sulfaydantion Library”, J. Comb. Chem., 3:290-300 (2001). |
| Almerico, et al., “On the Preparation of 1-aryl-2-heteroaryl- and 2-aryl-1-heteroaryl-pyrroles as Useful Building Blocks for Biologically Interesting Heterocycles”, ARKIVOC, Rudy Abramovitch Issue, pp. 129-142 (2001). |
| Antonescu, et al., “Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation,” Clinical cancer research : an official journal of the American Association for Cancer Research, 11(11):4182-4190 (2005). |
| Anzai, et al., “Alkyl- and Arylthiation of Uracil and Indole”, J. Heterocyclic Chem., 16:567-569 (1979). |
| Askew, et al., “Molecular Recognition with Convergent Functional Groups: 6. Synthetic and Structural Studies with a Model Receptor for Nucleic Acid Components”, J. Am. Chem., 111:1082-1090 (1989). |
| Avruch, J. et al., “Ras Activation of the Raf Kinase: Tyrosine Kinase Recmitment of the MAP Kinase Cascade,” Recent Prag Harm. Res. (2001) 56: 127-155. |
| Bai et al., “Targeting the KITactivating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation,” Leukemia (2013), vol. 27, pp. 278-285. |
| Bais, et al., “Inhibition of Endogenous Wxalate Production: Biochemical Consideration of the Roles of Glycollate Oxidase and Lactate Dehydrogenase”, Clinical Science, 76:303-309 (1989). |
| Baker, et al., “Irreversible Enzyme Inhibitors. 188. Inhibition of Mammalian Thymidine Phosphorylase”, Journal of Medicinal Chemistry, 14:612-616 (1971). |
| Barker, et al., “Characterization of pp60c-src Tyrosine Kinase Activities Using a Continuous Assay: Autoactivation of the Enzyme is an Intermolecular Autophosphorylation Process”, Biochemist , 35:14843-14851 (1995). |
| Barvian, et al., “Pyrido[2,3-d]pyrimidin-7-one Inhibitors of Cyclin-Dependent Kinases,” J Med Chem. (2000) 43:4606-4616. |
| Bausch, et al., “Proton-Transfer Chemistry of Urazoles and Related Imides, and Diacyl H drazides”, J. Org. Chem., 56:5643-5651 (1991). |
| Beghini, et al., “C-kit mutations in core binding factor leukemias,” Blood Journal, 95(2):726-727 (2000). |
| Benvenuti, et al., “Crystallization of Soluble Proteins in Vapor Diffusion for X-Ray Crystallography”, Nature Protocols, 2(7):1633-1651 (2007). |
| Blay, et al., “Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial”, Lancet Oncology, 21:923-934 (2020). |
| Bolton, et al., “Chapter 17. Ras Oncogene Directed Approaches in Cancer Chemotherapy,” Ann. Rep. Med. Chem. (1994) 29: 165-174. |
| Bosca, et al., “Circular Dichroism Analysis of Ligand-Induced Conformational Changes in Protein Kinase C”, Biochem J., 290:827-832 (1993). |
| Boschelli, et al., “4-Anilino-3-quinolinecarbonitriles: An Emerging Class of Kinase Inhibitors”, Current Topics in Medicinal Chemist, 2:1051-1063 (2002). |
| Bourdon NEC, et al., “Synthesis and Pharmacological Evaluation of New Pyrazolidine-3,5-diones as AT 1 Angiotensin II Receptor Antagonists”, J. Med. Chem., 43:2685-2697 (2000). |
| Boyer, “Small Molecule Inhibitors of KDR (VEGFR-2) Kinase: An Overview of Structure Activit Relationships”, Current Topics in Medicinal Chemist , 2:973-1000 (2002). |
| Brady, et al., “Fast Prediction and Visualization of Protein Binding Pockets with PASS”. Journal of Computer-Aided Molecular Desi n, 14:383-401 (2000). |
| Branford, et al., “High Frequency of Point Mutations Clustered Within the Adenosine Triphosphate-binding Region of BCR/ABL in Patients With Chronic Myeloid Leukemia or Ph-positive Acute Lymphoblastic Leukemia Who Develop Imatinib (ST1571)resistance,” Blood (2002) vol. 99, pp. 3472-3475. |
| Brasher, et al., “C-Abul has High Intrinsic Tyrosine Kinase Activity that is Stimulated by Mutation of the Src Homology 3 Domain and by Autophosphorylation at Two Distinct Re ulator T rosines”, Journal of Biolo ical Chemistr , 275:35631-35637 (2000). |
| Bullock, et al., “Prospects for Kinase Activity Modulators in the Treatment of Diabetes and Diabetic Complications”, Current Topics in Medicinal Chemistr , 2:915-938 (2002). |
| Byron, et al., “The Synthesis of some Substituted Biphenyl-4-carboxylic Acids, 4-Biphenylylacetic Acids, and 4-Aminobiphenyls”, J. Chem. Soc. (C), Organic, pp. 840-845 (1966). |
| Cardillo, et al., “Su lie 1,2-difenil-3.5-dichetopirazolidine”, Gazz. Chim., Ital., 9:973-985 (1966). |
| Carr, J. B., et al., “Isoxazolc Anthelmintics,” .J /'vied. Chem (1977) vol. 20, No. 7, pp. 934-939. |
| Chan, “Promotion of Reaction of N—H Bonds with Triarylbismuth and Cupric Acetate,” Tetrahedron Letters (1996) vol. 37, No. 50, pp. 9013-9016. |
| Chan, et al, “New N- and O-Arylations with Phenylboronic Acids and Cupric Acetate,” Tetrahedron Lett. (1998) 39:2933-2936. |
| Chan, et al., “Copper Promoted C—N and C—O Bond Cross-coupling With Phenyl and Pyridylboronates,” Tetrahedron Letters (2003) vol. 44, pp. 3863-3865. |
| Chen, et al., “Biochemical Evidence for the Autophosphorylation and Transphosphorylation of Transforming Growth Factor 13 Receptor Kinases”, Proc. Natl. Acad. Sci. USA, 92:1565-1569 (1995). |
| Cheng, et al., “Novel Solution Phase Strategy for the Synthesis of Chemical Libraries Containing Small Organic Molecules”, J. Am. Chem. Soc., 118:2567-2573 (1996). |
| Cheng, et al., “Synthesis and SAR of Heteroaryl-phenyl-substituted Pyrazole Derivatives as Highly Selective and Potent Canine COX-2 Inhibitors”, Bioorganic & Medicinal Chemistry Letters, 16:2076-2080 (2006). |
| Chu, et al., “Using Affinity Capillary Electrophoresis to Determine Binding Stoichiometries of Protein-Ligand Interactions”, Biochemistry, 33:10616-10621 (1994). |
| Cirillo, et al., “The Non-Diaryl Heterocycle Classes of p38 MAP Kinase Inhibitors”, Current Topics in Medicinal Chemistry, 2:1021-1035 (2002). |
| Clincial trial NCT02571036—A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies—clinicaltrials.gov—May 25, 2017. |
| Clincial trial NCT02571036—A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies—clinicaltrials.gov—Oct. 8, 2015. |
| Clincial trial NCT02571036—A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies—clinicaltrials.gov—Sep. 17, 2018. |
| Clinical trial NCT03353753 Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)—clinicaltrials.gov—Nov. 27, 2017. |
| Clinical trial NCT03353753 Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)—clinicaltrials.gov—Nov. 21, 2018. |
| Closier, et al., “Nitrofuryl Heterocyclics. 1”, Journal of Medicinal Chemistry, 13(4):638-640 (1970). |
| Cockerill, et al., “Small Molecule Inhibitors of the Class 1 Receptor Tyrosine Kinase Family”, Current Topics in Medicinal Chemistry, 2:1001-1010 (2002). |
| Col Ton, et al., “Affinity Capillary Electrophoresis: A Physical-Organic Tool for Studying Interactions in Biomolecular Recognition”, Electrophoresis, 19:367-382 (1998). |
| Corless, et al., “Biology of Gastrointestinal Stromal Tumors,” Journal of Clinical Oncology, 22(18):3813-3825 (2004). |
| Cortes, et al., “Results of Imatinib Mesylate Therapy in Patients with Refractory or Recurrent Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrime, and Mveloproliferative Disorders”, Cancer, 97(11 ):2760-2766 (2003). |
| Kwong, et al., “A General, Efficient, and Inexpensive Catalyst System for the Coupling Aryl Iodides and Thiols”, Organic Letters, 4(20):3517-3520 (2002). |
| Laskowski, “SURFNET: A Program for Visualizing Molecular Surfaces, Cavities, and Intermolecular Interactions”, Journal of Molecular Graphics, 13:323-330 (1995). |
| Leca, et al., “A New Practical One-Pot Access to Sulfonimidates”, Organic Letters, 4(23):4093-4095 (2002). |
| Lefevre, et al., “Roles of Stem Cell Factor/c-Kit and Effects of Glivec®/STI571 in Human Uveal Melanoma Cell Turmorigenesis”, Journal of Biological Chemistry, 279(30):31769-31779 (2004). |
| Lesort, et al., “Insulin Transiently Increases Tau Phosphorylation: Involvement of Glycogen Synthase Kinase-3f3 and Fyn Tyrosine Kinase”, Journal of Neurochemistry, 72(2):576-584 (1999). |
| Leung, et al., “The Difluoromethylensulfonic Acid Groups as a Monoanionic Phosphate Surrogate for Obtaining PTP1B Inhibitors”, Bioorganic & Medicinal Chemistry, 10:2309-2323 (2002). |
| Li, et al., “Targeting Serine/Threonine Protein Kinase B/Akt and Cell-cycle Checkpoint Kinases for Treating Cancer”, Current Topics in Medicinal Chemistry, 2:939-971 (2002). |
| Li, et al., “The P190, {210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia-like Syndrome in Mice but Have Different Lymphoid Leukemogenic Activity”, J. Exp. Med., 189(9):1399-1412 (1999). |
| Lim et al., “Current research and treatment for gastrointestinal stromal tumors” World Journal of Gastroenterology (2017), 23(27), 4856-4866 Publisher: Baishideng Publishing Group Inc. |
| Link, et al., “Synthesis of 8-Substituted 5-Deazaflavins”, J. Heterocyclic Chem, 22:841-848 (1985). |
| Lipinski, et al., “Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings”, Advanced Drug Delivery Reviews, 23:3-25 (1997). |
| Longley et al., “Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm,” Nature Genetics, 12(3):312-314 (1996). |
| Loren, et al., “NH-1,2,3-Triazoles from Azidomethyl Pivalate and Carbamates: Base-Labile N-Protecting Groups”, SYNLETT, 18:2847-2850 (2005). |
| Lorenzi, et al., “Amino Acid Ester Prodrugs of 2-Bromo-5, 6-dichloro-1-([3-D-ribofuranosyl)benzimidazole Enhance Metabolic Stability In Vitro and In Vivo,” The Journal of Phannaco/ogy and Experimental Therapeutics (2005) vol. 314, No. 2 pp. 883-890. |
| Lowinger, et al., “Design and Discovery of Small Molecules Targeting Raf-1 Kinase”, Current Pharmaceutical Design, 8:2269-2278 (2002). |
| Ma, et al., “c-MET Mutational Analysis in Small Cell Lung Cancer: Novel Juxtamembrane Domain Mutations Regulating Cytoskeletal Functions”, Cancer Research, 63:6272-6281 (2003). |
| Ma, et al., “c-Met: Structure, Functions and Potential for Therapeutic Inhibition”, Cancer and Metastasis Reviews, 22:309-325 (2003). |
| Magnuson, et al, “The Raf-I serine/threonine protein kinase,” Seminars in Cancer Biology. (1994) 5: 247-253. |
| Mallakpour, et al., “Uncatalyzed Polymerization of Bistriazolinediones with Electron-Rich Aromatic Compounds via Electrophilic Aromatic Substitution”, Journal of Polymer Science: Part A: Polymer Chemistry, 27:217-235 (1989). |
| Mamaev, et al., “Synthesis of 2,5′-Bipyrimidines from Substituted 5-Cyanopyrimidines”, Khimiya Geterotsiklicheskikh Soedinenni, 24(3):371-375—(1988). |
| March's Advanced Organic Chemisto.::: Reactions Mechanisms and Structure Fifth Edition, Smith and March Editors, Wiley-Interscience Publication (2001). |
| March, et al., “Tautomerism”, from March's Advanced Organic Chemisto.::, 4th Edition, WileyInterscience, pp. 69-74. |
| Martinez, et al., “First Non-ATP Competitive Glycogen Synthase Kinase 313 (GSK-313) Inhibitors: Thiadizolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimers Disease”, J. Med. Chem., 45(2002)1292-1299 (2002). |
| Mattsson, et al., “Six X-Linked Agammaglobulinemia-Causing Missense Mutations in the Src Homology 2 Domain of Bruton's Tyrosine Kinase: Phosphotyrosine-Binding and Circular Dichroism Analysis”, Journal of Immunoloav, pp. 4170-4177 (2000). |
| Mazzieri, R et al., Targeting The ANG2/TIE2 Axis Inhibits Tumor Growth And Metastasis By impairing Angiogenesis And Disabling Rebounds Of Proangiogenic Myelid Cells. Cell. Apr. 12, 2001, vol. 19, pp. 512-526; DOI: 10.1016/j.ccr.2001.02.005. |
| Mcpherson, “Current Approaches to Macromolecular Crystallization”, Eur. J. Biochem, 189:1-23 (1990). |
| Medebielle, et al., “A Convenient Synthesis of Perfluoroalkylated and Fluorinated-Aryl Nitrogen Bases by Electrochemically Induced SRN1 Substitution”, J. Org. Chem., 61:1331-1340 (1996). |
| Medebielle, et al., “A New Convenient Synthesis of 5-Aryl Uracils Using SRN1 Aromatic Nucleophilic Substitution”, Tetrahedron Letters, 34(21 ):3409-3412 (1993). |
| Mikhaleva, et al., “Relative Reactivities of the Chlorine Atoms of 2,2′,4-Trichloro-4′,5-Dipyrimidinyl in its Reaction with Piperidine”, Khimiya Geterotsiklicheskikh Soedinenii, 6:821-826 (1979). |
| Mol, “Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase,” The Journal Of Biological Chemistry, 279(30):31655-31663 (2004). |
| Morris, et al., “Automated Docking of Flexible Ligands to Macromolecules”, AutoDock Website, www.scripps.edu/mb/olson/doc/autodock/, printed March 3, (2005). |
| Morris, et al., “Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function”, Journal of Computational Chemistry, 19(14):1639-1662 (1998). |
| Morstyn, et al., “Stem Cell Factor Is a Potent Synergistic Factor in Hematopoiesis”, Oncology, 51 :205-214 (1994). |
| Moss, et al., “Basic Terminology of Stereochemistry”, Pure & Appl. Chem., 6812):2193-2222 (1996). |
| Muller, “Glossary of Terms Used in Physical Organic Chemistry”, Pure & Appl. Chem., 66(5):1077-1184 (1994). |
| Muller, et al., “A General Synthesis of 4-Substituted 1, 1-Dioxo-1,2,5-thiadiazolidin-3-ones Derived from a-Amino Acids”, J. Org. Chem., 54:4471-473 (1989). |
| Murayama, et al., “JNK (c-Jun NH2 Terminal Kinase) and p38 During Ischemia Reperfusion Injury in the Small Intestine” Transplantation, 81(9):1325-1330 (2006). |
| Mutlib, et al., “Disposition of 1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2′-(methylsulfonyl)-[1, 1 ′-biphenyl]-4-yl]-3(trifluomethyl)-1 H-pyrazole-5-carboxamide (DPC 423) by Novel Metabolic Pathways. Characterization of Unusual Metabolites by Liquid Chromatography/Mass Spectrometry and NMR”, Chem. Res. Toxicol., 15:48-62 (2002). |
| Mutlib, et al., “P450-Mediated Metabolism of 1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2′-(methylsulfonyl)-[1, 1 ′-biphenyl]-4-yl]-3(trifluomethyl)-1 H-pyrazole-5-carboxamide (DCP 423) and Its Analogues to Aldoximes. Characterization of Glutathione Conjugates of Postulated Intermediates Derived from Aloximes”, Chem. Res. Toxicol., 15:63-75 (2002). |
| Nagano, M. et al., “Studies on Organic Sulfur Compounds. XIV. The Reaction of N-alkoxycarbonyl-N′-(2-thiazolyl)thioureas with some oxidants.” Chemical and Pharmaceutical Bulletin. vol. 21, No. 11, pp. 2408-2416. ISSN: 0009-2363. Nov. 1973. |
| Nagar, et al., “Crystal Structures of the Kinase Domain of c-Abl in Complex with the Small Molecule Inhibitors PD173955 and Imatinib (STI-571 )”, Cancer Research, 62:4236-4243 (2002). |
| Nagata, et al., “Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder,” Proc. Natl. Acad. Sci. USA, 92(23):10560-10564 (1995). |
| Nager, et al., “Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase,” Cell (Mar. 21, 2003) vol. 112, pp.859-871. |
| Nakopoulou, et al., “c-Met Tyrosine Kinase Receptor Expression is Associated with Abnormal !3-catenin Expression and Favourable Prognostic Factors in Invasive Breast Carcinoma”, Histopatholoav, 36:313-325 (2000). |
| Nantaka-Namirski, et al., “Condensation Reaction of Ethyl (4-Uracil)-Acetate with Ethyl Orthoformate”, ACTA Polon. Pharm XXVII, 28(5):455-463 (1971). |
| National Academy of Sciences, “Abstracts of Papers Presented at the Autumn Meeting, Nov. 14-16, 1960”, Science, 132:1488-1501 (1960). |
| Nicolaou, et al., “Molecular Design and Chemical Synthesis of a Highly Potent Epothilone”, ChemMedChem, 1 :41-44 (2006). |
| Nikolaev, et al., “Solubility Polytherm in the System HNO3-H2O-(C4H9O)PO(C4H9)2”, Dokladv Akademii Nauk SSSR, 160(4):841-844 (1965). |
| Ning, et al., “Activating Mutations of c-Kit at Codon 816 Confer Drug Resistance in Human Leukemia Cells,” Leukemia and Lymphoma, 41(5-6):513-522 (2001). |
| Nofal, et al., “Synthesis of Novel Uracil-5-Sulphonamide Derivatives of Possible Biological Activity”, Egypt J. Chem., 33(4):375-380 (1990). |
| U.S. Appl. No. 11/963,740, filed Dec. 21, 2007, Patented, U.S. Pat. No. 8,163,756. |
| U.S. Appl. No. 11/870,388, filed Oct. 10, 2007, Patented, U.S. Pat. No. 7,790,756. |
| U.S. Appl. No. 12/829,561, filed Jul. 2, 2010, Patented, U.S. Pat. No. 8,586,565. |
| U.S. Appl. No. 11/854,354, filed Sep. 12, 2007, Patented, U.S. Pat. No. 8,188,113. |
| U.S. Appl. No. 10/746,460, filed Dec. 24, 2003, Patented, U.S. Pat. No. 7,144,911. |
| U.S. Appl. No. 10/886,329, filed Jul. 6, 2004, Patented, U.S. Pat. No. 7,202,257. |
| U.S. Appl. No. 11/450,840, filed Jun. 9, 2006, Patented, U.S. Pat. No. 7,342,037. |
| U.S. Appl. No. 11/336,708, filed Jan. 20, 2006, Patented, U.S. Pat. No. 7,531,566. |
| U.S. Appl. No. 11/450,850, filed Jun. 9, 2006, Patented, U.S. Pat. No. 7,666,895. |
| U.S. Appl. No. 10/746,607, filed Dec. 24, 2003, Patented, U.S. Pat. No. 7,279,576. |
| U.S. Appl. No. 11/854,293, filed Sep. 12, 2007, Patented, U.S. Pat. No. 7,897,762. |
| U.S. Appl. No. 12/105,408, filed Apr. 18, 2008, Patented, U.S. Pat. No. 8,143,293. |
| U.S. Appl. No. 13/590,955, filed Aug. 21, 2012, Patented, U.S. Pat. No. 8,486,951. |
| U.S. Appl. No. 11/450,849, filed Jun. 9, 2006, Patented, U.S. Pat. No. 7,737,283. |
| U.S. Appl. No. 13/785,575, filed Mar. 5, 2013, Patented, U.S. Pat. No. 8,741,911. |
| U.S. Appl. No. 12/608,578, filed Oct. 29, 2009, Patented, U.S. Pat. No. 8,278,331. |
| U.S. Appl. No. 13/098,247, filed Apr. 29, 2011, Patented, U.S. Pat. No. 8,569,319. |
| U.S. Appl. No. 13/559,170, filed Jul. 26, 2012, Patented, U.S. Pat. No. 8,637,672. |
| U.S. Appl. No. 14/214,134, filed Mar. 14, 2014, Patented, U.S. Pat. No. 9,133,183. |
| U.S. Appl. No. 14/383,803, filed Mar. 5, 2013, Patented, U.S. Pat. No. 9,187,474. |
| U.S. Appl. No. 13/491,394, filed Jun. 7, 2012, Patented, U.S. Pat. No. 8,461,179. |
| U.S. Appl. No. 13/801,753, filed Mar. 13, 2013, Patented, U.S. Pat. No. 8,940,756. |
| U.S. Appl. No. 16/387,315, filed Apr. 17, 2019, Pending. |
| U.S. Appl. No. 14/214,127, filed Mar. 14, 2014, Patented, U.S. Pat. No. 9,012,635. |
| U.S. Appl. No. 13/683,277, filed Nov. 21, 2012, Patented, U.S. Pat. No. 8,921,565. |
| U.S. Appl. No. 14/549,125, filed Nov. 20, 2014, Patented, U.S. Pat. No. 9,387,202. |
| U.S. Appl. No. 14/214,160, filed Mar. 14, 2014, Patented, U.S. Pat. No. 9,193,719. |
| U.S. Appl. No. 14/214,171, filed Mar. 14, 2014, Patented, U.S. Pat. No. 9,181,223. |
| U.S. Appl. No. 14/214,185, filed Mar. 14, 2014, Patented, U.S. Pat. No. 9,382,228. |
| U.S. Appl. No. 14/214,179, filed Mar. 14, 2014, Patented, U.S. Pat. No. 9,309,224. |
| U.S. Appl. No. 14/383,799, filed Mar. 5, 2013, Patented, U.S. Pat. No. 9,334,267. |
| U.S. Appl. No. 14/535,900, filed Nov. 7, 2014, Patented, U.S. Pat. No. 9,457,019. |
| U.S. Appl. No. 15/957,888, filed Apr. 19, 2018, Pending, US 2019-0091217 A1. |
| U.S. Appl. No. 16/617,721, filed Nov. 27, 2019, Pending, US 2020-0129489 A1. |
| U.S. Appl. No. 17/028,591, filed Sep. 22, 2020, Pending, US 2021-0015801 A1. |
| U.S. Appl. No. 16/943,821, filed Jul. 30, 2020, Pending. |
| U.S. Appl. No. 16/725,282, filed Dec. 23, 2019, Pending, US 2020-0253973 A1. |
| U.S. Appl. No. 16/870,384, filed May 8, 2020, Pending, US 2020-0354352 A1. |
| U.S. Appl. No. 16/870,418, filed May 8, 2020, Pending, US 2020-0354346 A1. |
| U.S. Appl. No. 16/902,989, filed Jun. 16, 2020, Pending. |
| U.S. Appl. No. 16/991,644, filed Aug. 12, 2020, Pending. |
| U.S. Appl. No. 17/028,640, filed Sep. 22, 2020, Pending. |
| U.S. Appl. No. 17/180,218, filed Feb. 19, 2021, Pending. |
| U.S. Appl. No. 17/180,234, filed Feb. 19, 2021, Pending. |
| U.S. Appl. No. 17/180,241, filed Feb. 19, 2021, Pending. |
| Nowell, et al., “A Minute Chromosome in Human Chronic Granulocytic Leukemia,” Science (Nov. 18, 1960) vol. 132, p. 1497. |
| O'Dell, et al., “Treatment of Rheumatoid Arthritis with Methotrexate Alone, Sulfasalazine and Hydroxychloroquine, or a Combination of All Three Medications”, New England J. Med., 334(20):1287-1291 (1996). |
| O'Neill, “Targeting Signal Transduction as a Strategy to Treat Inflammatory Diseases”, Nature Review Drug Discovery, Published Online Jun. 9, 2006, www.nature.com/reviews/druqdisc. |
| Okano, et al., “o-Bromophenylzinc Compound: A Readily Available and Efficient Synthetic Equivalent of o-Phenylene 1-Anion 2-Cation”, Tetrahedron Letters 39:3001-3004 (1998). |
| Okishio, et al., “Differential Ligand Recognition by the Src and Phosphatidylinositol 3-Kinase Src Homology 3 Domains: Circular Dichroism and Ultraviolet Resonance Raman Studies”, Biochemistry, 42:208-216 (2003). |
| Okishio, et al., “Identification of Tyrosine Residues Involved in Ligand Recognition by the Phosphatidylinositol 3-Kinase Src Homology 3 Domain: Circular Dichroism and UV Resonance Raman Studies”, Biochemistrv, 40:15797-15804 (2001). |
| Okishio, et al., “Role of the Conserved Acidic Residue Asp21 in the Structure of Phosphatidylinositol 3-Kinase Src Homolgy 3 Domain: Circular Dichroism and Nuclear Magnetic Resonance Studies”, Biochemistry 40:119-129 (2001). |
| Okram, Barun et al: “A General Strategy for Creating “Inactive-Conformation” Ab1 Inhibitors” Chemistry&Biology (Cambridge, MA, US), 13(7), 779-786 CODEN: CBOLE2; ISSN: 1074-5521, 2006, XP002469183 table 1 the whole document. |
| Palmer, Brian, D. et al: “Structure-Activity Relationships For 2-Anilino-6-Phenylpyrido[2,3-d]Pyrimidin-7(8H)-Ones As Inhibitors of the Cellular Checkpoint Kinase Wee1” Bioorganic & Medicinal Chemistry Letters, 15(7), 1931-1935 CODEN: BMCLE8; ISSN: 0960-894X, 2005, XP004789411 p. 1933. |
| Parang, et al., “Mechanism-based Design of a Protein Kinase Inhibitor”, Nature Structural Bioloav, 8( 1 ):37-41 (2001). |
| Pargellis, et al., “Inhibition of p38 MAP Kinase by Utilizing a Novel Allosteric Binding Site”, Nature Structural Bioloav, 9(4 ):268-272 (2002). |
| Park, et al., “Mechanism of met Oncogene Activation”, Cell, 45:895-904 (1986). |
| Pearlman, et al., “Assisted Model Building with Energy Refinement”, Amber Home Page, amber.scripts.edu. |
| Pedersen, “The Preparation of Some N-Methyl-1,2,3-Triazoles”, Acta Chimica Scandinavica, 13(5):888-892 (1959). |
| Peng, et al., “Identification of Novel Inhibitors of BCR-ABL Tyrosine Kinase via Virtual Screening”, Bioorganic & Medicinal Chemistry Letters, 13:3693-3699 (2003). |
| Pereira, et al., “The Role of c-kit and Imatinib Mesylate in Uveal Melanoma”, Journal of Carcinogenesis, 4:19 (2005), downloaded from www.carcinogenesis.com/content/4/1/19, Sep. 3, 2008. |
| Peyssonnaux, C. et al., “The RaflMEK/ERK pathway: new concepts of activation,” Biol. Cell (2001) 93: 53-62. |
| Picard, et al., Inhibitors of Acyl-CoA: Cholesterol O-Acyltrasferase. 17. Structure-Activity Relationships of Several Series of Compounds. |
| Pierrat, et al., “Solid Phase Synthesis of Pyridine-Based Derivatives from a 2-Chloro-5-Bromopyridine Scaffold,” .J Comb. Chem. (2005) 7 (6): 879-886. |
| Pluk, et al., “Autoinhibition of c-Abl,” Cell (Jan. 25, 2002) vol. 108, pp. 247-259. |
| Ponzetto, et al., “A Novel Recognition Motif for Phosphatidylinositol 3-Kinase Binding Mediates Its Association with the Hepatocyte Growth Factor/Scatter Factor Receptor”, Molecular and Cellular Bioloav, 13(8):4600-4608 (1993). |
| Raimbaul T, et al., “Effects of pH and KCI on the Conformations of Creatine Kinase from Rabbit Muscle”, Eur. J. Biochem., 234:570-578 (1995). |
| Ranatunge, et al, “Synthesis and Selective Cyclooxygenase-2 Inhibitory Activity of a Series of Novel, Nitric Oxide Donor-Containing Pyrazoles,” J Med Chem. (2004) 47: 2180-2193. |
| Rebek, et al. “Convergent Functional Groups: Synthetic and Structural Studies”, J. Am. Chem. Soc., 107:7476-7481 (1985). |
| Rebek, et al., “Convergent Functional Groups. 2. Structure and Selectivity in Olefin Epoxidation with Peracids”, J. Org. Chem., 51:1649-1653 (1986). |
| Reed, et al., “Circular Dichroic Evidence for an Ordered Sequence Ligand/Binding Site Interactions in the Catalytic Reaction of the cAMP-Dependent Protein Kinase”, Biochemistry, 24:2967-2973 (1985). |
| Regan, et al., “Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate”, J. Med. Chem., 45:2994-3008 (2002). |
| Regan, et al., “Structure-Activity Relationships of the p38a MAP Kinase Inhibitor 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl )-3-[4-(2-morpholi n-4-yl-ethoxy)naph-thalen-1-yl]urea (BI RB 796)”, J. Med. Chem., 46:4676-4686 (2003). |
| Rooney, et al., “Inhibitors of Gylcolic Acid Oxidase. 4-Substituted 3-Hydroxy-1 H-pyrrole-2,5-dione Derivatives”, J. Med. Chem., 26(5):700-714 (1983). |
| Roux, et al., “ERK and p38 MAPK-Activated Protein Kinases: a Family of Protein Kinases with Diverse Biological Functions”, Microbiology and Molecular Biology Reviews, 68(2):320-344 (2004). |
| Rowley, “A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Flourescence and Giemsa Staining,” Nature (Jun. 1, 1973) vol. 243, pp. 290-293. |
| Rubin, et al., “Gastrointestinal stromal tumour,” The Lancet Oncology, 369(9574):1731-1741 (2007). |
| Russell, et al., “3-[3-(Piperdin-1-yl)propyl]indoles as Highly Selective h5-HT1D Receptor”, J. Med. Chem., 42:4981-5001 (1999). |
| Rutkowski, et al., “Gastrointestinal stromal tumours (GIST)—2018”, Oncology in Clinical Practice, 14(6):399-407 (2019). |
| Saiga, et al., “Consecutive Cross-Coupling of o-Phenylenedizinc Compound with Acyl and/or Aryl Halides in the Presence of Pd(0)-tris(2,4,6-trimethoxyphenyl)phosphine”, Tetrahedron Letters, 41 :4629-4632 (2000). |
| Sakamoto, et al., “Condensed Heteroaromatic Ring Systems. XIX. Synthesis and Reactions of 5-(Tributylstannyl)Isoxazoles”, Tetrahedron, 4 7(28):5111-5118 (1991). |
| Sakuma, et al., “c-kit Gene Mutations in Intracranial Germinomas”, Cancer Sci, 95(9):716-720 (2004). |
| Salgia, “Studies on c-Kit and c-Met in Lung Cancer with Similarities to Stem Cells,” Microscopy Society of America, 11(2):1-30 (2005). |
| Satsangi, et al., “1-(4-Substituted-thiazol-2-yl)hydatoins as Anti-inflammatory and CNS Active Agents”, Pharmazie, 38:341-342 (1983). |
| Sawyers, “Chronic Myeloid Leukemia,” The New England Journal of Medicine (Apr. 29, 1999) vol. 340, No. 17, pp. 1330-1340. |
| Schindler, et al., “Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase.” Science (Sep. 15, 2000) vol. 289, pp. 1938-1942. |
| Schlosser, et al., “Regiochemically Flexible Substitutions of Di-, Tri-, and Tetrahalopy:ridines: The Trialkylsily Trick,” J Org. Chem. (2005) 70: 2494-2502. |
| Schmidt, et al., “Germline and Somatic Mutations in the Tyrosine Kinase Domain of the MET proto-oncogene in Papillary Renal Carcinomas”, Nature Genetics, 16:68-73 (1997). |
| Schmidt, et al., “Novel Mutations of the MET Proto-oncogene in Papillary Renal Carcinomas”, Oncoqene, 18:2343-2350 (1999). |
| Schneeweiss Mathias, et al., “The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis,” Haematologica (2018) vol. 103, No. 5, pp. 799-809. |
| Schneeweiss Mathias, et al., “The Multi-Kinase Inhibitor DCC-2618 Inhibits Proliferation and Survival of Neoplastic Mast Cells and Other Cell Types Involved in Systemic Mastocytosis,” Blood (2016) vol. 128, No. 22, pp. 1965. |
| Seimiya, et al., “Telomere Shortening and Growth Inhibition of Human Cancer Cells by Novel Synthetic Telomerase Inhibitors MST-312, MST-295, and MST-199”, Molecular Cancer Therapeutics, 1:657-665 (2002). |
| Seminario, et al., “Theoretical Study of a Molecular Resonant Tunneling Diode”, J. Am. Chem. Soc., 122:3015-3020 (2000). |
| Seto, et al. “2-Substituted-4-aryl-6, 7 ,8,9-tetrahydro-5/ 1-p)'Timido [ 4, 5-b] [ 1,5 Joxazocin-5-oneasastrncturallynewNK1 antagonist,” Biorg Nied Chem. Tea. (2005) 15: 1485-1488. |
| Shah, et al., “Circular Dichroic Studies of Protein Kinase C and its Interactions with Calcium and Lipid Vesicles”, Biochimica et Biophysica Acta, 1119:19-26 (1992). |
| Heinrich, et al., “Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors,” Journal of Clinical Oncology, 24(29):4764-4774 (2006). |
| Heinrich, et al., “Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor,” Journal of Clinical Oncology, 26(33):5352-5359 (2008). |
| Honda, et al., “Determination of the Association Constant of Monovalent Mode Protein-Sugar Interaction by Capillary Zone Electrophoresis”, Journal of Chromatography, 597:377-382 (1992). |
| Hu, et al., “Capillary Electrophoresis for the Analysis of Biopolymers”, Anal., Chem., 74:2833-2850 (2002). |
| Huang, et al., “Inhibition of Nucleoside Transport by Protein Kinase Inhibitors”, The Journal of Pharmacolo and Experimental Therapeutics, 304 2 :753-760 (2003). |
| Hubbard, “Crystal Structure of the Activated Insulin Receptor Tyrosine Kinase in Complex with Peptide Substrate and ATP Analo”, EMBO, 16(18):5573-5581 (1997). |
| Hubbard, et al., “Crystal Structure of the Tyrosine Kinase Domain of the Human Insulin Receptor”, Nature, 374:746-754 (1994). |
| Hughes, et al., “Modulation of the Glycogen Synthase Kinase-3 Family by Tyrosine Phosphor lation”, EMBO, 122 :803-808 (1993). |
| Huse, et al., “Crystal Structure of the Cytoplasmic Domain of the Type I TGFI3 Receptor in Complex with FKBP12”, Cell, 96:425-436 (1999). |
| Huse, et al., “The Conformational Plasticity of Protein Kinases,” Cell (May 3, 2002) vol. 109, pp. 275-282. |
| Huse, et al., “The TGFI3 Receptor Activation Process: An Inhibitor- to Substrate-Binding Switch”, Molecular Cell, 8:671-682 (2001). |
| Igarashi, et al., “Antimicrobial Activities of 2-arylthio-N-alkylmaleimides”, Journal of Industrial Microbiolo, 9:91-96 (1992). |
| International Human Genome Sequencing Consortium, “Initial Sequencing and Analysis of the Human Genome”, Nature, 409:860-921 (2001). |
| International Search Report and Written Opinion from PCT/US2012/041378, mailed Sep. 17, 2012. |
| International Search Report and Written Opinion from PCT/US2017/035005, mailed Feb. 22, 2018. |
| International Search Report and Written Opinion from PCT/US2019/016148, mailed Apr. 17, 2019. |
| International Search Report and Written Opinion from PCT/US2019/016161, mailed Apr. 23, 2019. |
| International Search Report and Written Opinion from PCT/US2020/045876, mailed Oct. 22, 2020. |
| International Search Report and Written Opinion from WO2008/034008 A3, mailed Apr. 11, 2008. |
| International Search Report issued for PCT/US2008/060833, mailed Sep. 30, 2008. |
| International Search Report issued for PCT/US2008/060867, mailed Sep. 29, 2008. |
| International Search Report issued for PCT/US2008/060896, mailed Sep. 29, 2008. |
| Ishida, et al., “Molecular Arrangement and Electrical Conduction of Self-Assembled Monola ers Made from Terphen I Thiols”, Surface Sciences, 514:187-193 (2002). |
| Islip, et al., “Nitrofuryl Heterocyclics 3”, Journal of Medicinal Chemistry, 16(11 ): 1309-1310 (1973). |
| Jackson, et al., “N-Terminal Mutations Activate the Leukemogenic Potential of the M risto lated form of c-abl”, EMBO, 8(2):449-456 (1989). |
| Jackson, et al., “Pyridinylimidazole Based p38 MAP Kinase Inhibitors”, Current Topics in Medicinal Chemist, 2:1011-1020 (2002). |
| Janku Filip et al., “Pharmacokinetic-driven phase I study of DCC-2618 a pan-KIT and PDGFR inhibitor in patients (pts) with gastrointestinal stromal tumor (GIST) and other solid tumors,” J. Clin. Oncol. (2017) No. 15, Suppl 2515. |
| Janku, et al., “Abstract CT058: Ripretinib (DCC-2618) pharmacokinetics (PK) in a Phase I study in patients with gastroinestinal stromal tumors (GIST) and other advanced malignancies: A retrospective evaluation of the PK effects of proton pump inhibitors (PPIs)”, American Association for Cancer Research, 79(13):1-4 (2019). |
| Jiang, et al., “Soft Docking”: Matching of Molecular Surface Cubes, J. Mol. Biol., 219:79-102 (1991). |
| Jiang, et al., “Synthesis and SAR Investigations for Novel Melanin-Concentrating Hormone 1 Receptor (MCH1) Antagonists Part 1. The Discovery of Arylacetamides as Viable Replacements for the Dihydropyrimidione Moiety of an HTS Hit”, J. Med. Chem., 50:3870-3882 (2007). |
| Johnson, “Circular Dichroism Spectroscopy and The Vacuum Ultraviolet Region”, Ann. Rev. Phys. Chem., 29:93-114 (1978). |
| Johnson, “Protein Secondary Structure and Circular Dichroism: A Practical Guide”, Proteins: Structure, Function, and Genetics, 7:205-214 (1990). |
| Johnson, et al., “An Evaluation of the Effect of Light Stabilisers on the Exterior Durability of Polyester Powder Coatings for the Architectural Market”, Surface Coatings International, 3:134-141 (1999). |
| Johnson, et al., “The Stereochemistry of Oxidation at Sulfur Oxidation of 2-Thiabicyclo[2.2.1 ]Hpetane”, Tetrahedron, 25:5649-5653 (1969). |
| Katritzky, et al., “Novel Chromophoric Heterocycles Based on Maleimide and Naphthoquinone”, J. Heterocyclic Chem., 26:885-892 (1989). |
| Kern, et al., “Synthese von Makromolekeln einheitlicher Brol3e. II Mitt: Syntheses neuer Diololigo-urethane nach dem Duplikationsverfahren”, Makromolekulara Chemie, 16:89-107 (1955). |
| Kettle et al., “Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors” Journal of Medicinal Chemistry (2018), 61(19), 8797-8810. |
| Kim, et al., “Solid Phase Synthesis of Benzamidine and Butylamine-Derived Hydantoin Libraries”, Molecular Diversity, 3:129-132 (1998). |
| Klayman, et al., “The Reaction of S-Methiodide Derivatives of Activated Thioureas with Hydroxylic Compounds. A Novel Synthesis of Mercaptans”, J. Org. Chem., 37(10):1532-1537 (1972). |
| Kleywegt, et al., “Detection, Delineation, Measurement and Display of Cavities in Macromolecular Structures”, Acta Cryst, D50:178-185 (1994). |
| Koch, et al., “QSAR and Molecular Modelling for a Series of Isomeric X-Sulfanilamido-1-phenylpyrazoles”, Quant. Struct. Act. Relat., 12:373-382 (1993). |
| Kolch, W., “Meaningful relationships: the regulation of the Ras/Raf/MEKJERK pathway by protein interactions,” Biochem. J (2000) 351: 289-305. |
| Konopka, et al., “Cell Lines and Clinical Isolates Derived From Ph-positive Chronic Myelogenous Leukemia Patients Express c-abl Proteins With A Common Structural Alteration,” Proc. Natl. Acad. Sci. (Mar. 1985) vol. 82, pp. 1810-1814. |
| Krasovitskii, et al., “Synthesis and Spectral-Luminescence Properties of Hetarylethylene Derivatives of 2,5-Diphenyloxazole and 2,5-Diphenyl-1,3,4-Oxadiazole”, Khimiya Geterotsiklicheskikh Soedinenii, 5:617-621 (1982). |
| Kuhn, et al., “The Genesis of High-Throughput Structure-Based Drug Discovery using Protein Crystallography”, Analytical Techniques, Current Opinion in Chemical Biology, 6:704-710 (2002). |
| Kumar, et al., “P38 Map Kinases: Key Signalling Molecules as Therapeutic Targets for Inflammatory Diseases”, Nature Reviews Drug Discovery, 2:717-726 (2003). |
| Kundrot, “Which Strategy for a Protein Crystallization Project”, CMLS, Cell. Mol. Life Sci., 61 :525-536 (2004). |
| Kundu, et al., “Depropargylation Under Palladium-Copper Catatlysis: Synthesis of Diaryl Sulfides”, Tetrahedron, 57:5885-5895 (2001). |
| Kurogi, et al., “Discovery of Novel Mesangial Cell Proliferation Inhibitors Using a Three-Dimensional Database Searching Method”, J. Med. Chem., 44:2304-2307 (2001). |
| Kuse, et al., Synthesis of azide-fluoro-dehydrocoelentcrazine analog as a photoaffinitylabeling probe and photolysis of azide-fluoro-coelenterazine; Tetrahedron Lett. (2005) 61: 5754-5762. |
| Cortes, Javier, et al., “Eribulin Monotherapy Versus Treatment of Physician's Choice in Patients With Metastatic Breast Cancer (EMBRACE): A Phase 3 Open-label Randomised Study”, The Lancet, vol. 377, No. 9769, Mar. 1, 2011 (Mar. 1, 2011), pp. 914-923, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(11 )60070-6. |
| Cross, et al., “Inhibition of Glycogen Synthase Kinase-3 by Insulin Mediated by Protein Kinase B”, Nature, 378:785-789 (1995). |
| Cudney, “Preface: Protein Crystallization and Dumb Luck”, The Rigaku Journal, 16(1): 1-7 (1999). |
| Dajani, et al., “Crystal Structur of Glycogen Synthase Kinas 3j3: Structural Basis for Phosphate-Primed Substrate Specificity and Autoinhibition”, Cell, 105:721-732 (2001). |
| Dajani, et al., “Structural Basis for Recruitment of Glycogen Synthase Kinase 313 to the Axin-APC Scaffold Complex”, EMBO, 22(3):494-501 (2003). |
| Daley, et al., “Induction of Chronic Myelogenous Leukemia in Mice by the P21 otcriat, Gene of the Philadelphia Chromosome,” Science (Feb. 16, 1990) vol. 247, pp. 824-830. |
| Database Registry [Online] Chemical Abstracts Service, Columbus, Ohio, US; May 27, 2010, XP002777425, retrieved from STN accession No. 1225278-16-9 RN (2 pages). |
| Davies, H. et al., “Mutations of the BRAF gene in human cancer,” Nature (Jun. 2002) 41 7: 949-954. |
| Davis, et al., “Iterative Size-Exclusion Chromatography Coupled with Liquid Chromatographic Mass Spectrometry to Enrich and Identify Tight-Binding Ligands from Complex Mixtures”, Tetrahedron, 55:11653-11667 (1999). |
| De Boer, et al., “Synthesis and Characterization of Conjugated Mono- and Dithiol Oligomers and Characterization of Their Self-Assembled Monolayers”, Langmuir, 19:4272-4284 (2003). |
| De Palma et al., “Angiopoietin-2 TIEs Up Macrophages in Tumor Angiogenesis” Clin Cancer Res; 17(16) Aug. 15, 2011. |
| De Silva, et al., “Gastrointestinal Stromal Tumors (GIST): C-kin Mutations, CD117 Expression, Differential Diagnosis and Targeted Cancer Therapy with Imatinib”, Pathology Oncology Research, 9(1 ):13-19 (2003). |
| Debiec-Rychter, et al., “Mechanisms of Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumors and Activity of the PKC412 Inhibitor Against Imatinib-Resistant Mutants,” Gastroenterology, 128(2):270-279 (2005). |
| Deciphera Pharmaceuticals LLC, “DCC-2618, a small molecule inhibitor of normal and mutant KIT kinase for treatment of refractory gastrointestinal stromal tumors (GIST)” (Presented on Sep. 24, 2011 at GIST Summit 2011 on “Gastrointestinal stromal tumors.”). |
| Deciphera Pharmaceuticals LLC, “Deciphera Pharmaceuticals announces positive top-line results from INVICTUS pivotal phase 3 clinical study of Ripretinib in patients with advanced gastrointestinal stromal tumors”, 1-3 (2019). |
| Deciphera Pharmaceuticals LLC, “Deciphera Pharmaceuticals Initiates Pivotal Phase 3 Clinical Study of Ripretinib (DCC-2618) in Second-line Patients with Gastrointestinal Stromal Tumors (“INTRIGUE” Study)”, 1-2 (2018). |
| Deciphera Pharmaceuticals LLC, “Qinlock Full Prescribing Information”, 1-18 (2020). |
| Deng, et al., “Expression, Characterization, and Crystallization of the Pyrophosphate-Dependent Phosphofructo-1-Kinase of Borrelia Burgdorferi”, Archives of Biochemistry and Biophysics, 371(2):326-331 (1999). |
| Dess, et al., “A Useful 12-1-5 Triacetoxyperiodiane (the Dess-Martin Periodiane) for Selective Oxidation of Primary or Secondary Alcohols and a Variety of Related 12-1-5 Species”, J. Am. Chem., Soc., 113:7277-7287 (1991). |
| Dong, J., Overcoming Resistance To BRAF And MEK inhibitors By Simultaneous Suppression Of CDK4. InTech. Jan. 30, 2013. Melanoma—From Early Detection to Treatment, Chapter 1; abstract; p. 7, second paragraph; p. 9, figure 4; DOI: 10.5772/53620. |
| Dumas, “Preface”, Current Topics in Medicinal Chemistry (2002). |
| Dumas, “Protein Kinase Inhibitors: Emerging Pharmacophores”, Exp. Opin. Ther. Patent, 11 :405-429 (2001). |
| Dumas, et al., “Discovery of a New Class of p38 Kinase Inhibitors”, Bioorganic & Medicinal Chemistry Letters, 10:2047-2050 (2000). |
| Dumas, et al., “Recent Developments in the Discovery of Protein Kinase Inhibitors From the Urea Ciass,” Current Opinion in Drug Discovery & Development (2004) vol. 7, No. 5, pp. 600-616. |
| Ettmayer, et al., “Lessons Learned from Marketed and Investigational Prodrugs,” Journal of Medicinal Chemistry (May 6, 2004) vol. 47, No. 10, pp. 2393-2404. |
| Ewing, “Critical Evaluation of Search Algorithms for Automated Molecular Docking and Database Screeninq”, Journal of Computational Chemistry, 18(9):1175-1189 (1997). |
| Examination Report in Indian Patent App. No. 11241/DELNP/2014 mailed Apr. 1, 2019. |
| Faderl, et al., “The Biology of Chronic Myeloid Leukemia,” The New England Journal of Medicine (Jul. 15, 1999) vol. 341. No. 3, pp. 164-172. |
| Farooqui, et al., “Interactions Between Neural Membrane Glycerophospholipid and Sphingolipid Mediators: A Recipe for Neural Cell Survival or Suicide”, Journal of Neuroscience Research, 85:1834-1850 (2007). |
| Fathalla, “Synthesis of New Pyrazolo[1,5-a]pyrimidine Derivative Using 5-Aminouracil and Ketene Dithiacetal”, Arch Pharm Res, 22(6):571-574 (1999). |
| Fathalla, et al., “Synthesis of New Uracil-5-Sulfonamide Derivatives and Immuno-Stimulatory Effect of a Chemically Modified Hemolymph of Biomphalaria Alexandrina on Schistosoma Manosi Infected Mice”, Arch Pharm Res., 26(5):358-366 (2003). |
| Fathalla, et al., “Synthesis of New Uracil-5-Sulphonamide-p-Phenyl Derivatives and Their Effect on Biomphalaria Alexandrina Snail's Nucleoproteins”, Arch. Pharm. Res., 23(2):128-138 (2000). |
| Flatt, et al., “Synthesis of Thiol Substituted Oligoanilines for Molecular Device Candidates”, Tetrahedron Letters, 44:6699-6702 (2003). |
| Fletcher, et al., “Diagnosis of Gastrointestinal Stromal Tumors: A Consensus Approach”, 33(5):459-465 (2002). |
| Fletcher, et al., “KIT Mutations in GIS, Current Opinion in Genetics & Development,” Science Direct, p. 3-7 (2007). |
| Frame, et al., “A Common Phosphate Binding Site Explains the Unique Substrate Specificity of GSK3 and Its Inactivation by Phosphorylation”, Molecular Cell, 7:1321-1327 (2001). |
| Furyua, et al., “Addition of 4-Ethoxyimidazoles to Dimethyl Acetylenedicarboxylate and Transformation of the Adducts to Pyrimidian-5-yl Acetates”, Chem. Pharm. Bull., 36(5):1669-1675 (1988). |
| Gajiwala, et al., “KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients,” Proceedings of the National Academy of Sciences of the USA 106(5):1542-1547 (2009). |
| Garcia-Tellado, et al., “Molecular Recognition in the Solid Waste State: Controlled Assembly of Hydrogen-Bonded Molecular Sheets”, J. Am. Chem. Soc., 113:9265-9269 (1991). |
| George, et al., “Initial Results of Phase 1 Study of DCC-2618, a Broad-Spectrum Kit and PDGFRA Inhibitor, in Patients (PTS) with Gastrointestinal Stromal Tumor (GIST) by Number of Prior Regimes”, European Society for Medical Oncology, 1-13 (2018). |
| Gishizky, et al., “Efficient transplantation of BCR-ABL-induced Chronic Myelogenous Leukemia-like Syndrome in Mice,” Proc. Natl. Acad. Sci. (Apr. 1993) vol. 90, pp. 3755-3759. |
| Gorre, et al., “Clinical Resistance to STI-571Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification,” Science (Aug. 3, 2001) vol. 293, pp. 876-880. |
| Greene, et al., “Chapter 7: Protection for the Amino Group”, in Protective Groups in Organic Synthesis, Third Edition, pp. 494-653 (1999). |
| Griffith, et al., “TPAP: Tetra-n-propylammonium Perruthenate, A Mild and Convenient Oxidant for Alcohols”, Aldrichimica Acta, 23(1):13-19 (1990). |
| Guzel, “Investigation of the Relationship Between the Inhibitory Activity of Glycolic Acid Oxidase (GAO) and its Chemical Structure: Electron-Topological Approach”, Journal of Molecular Structure, 366:131-137 (1996). |
| Haar, et al., “Structure of GSK313 Reveals a Primed Phosphorylation Mechanism”, Nature Structural Bioloav, 8(7):593-596 (2001). |
| Hackler, et al., “The Syntheses of 5-Amino-3-t-butylisothiazole and 3-Amino-5-t-butylisothiazole,” J. Heterocyclic Chem. (Nov.-Dec. 1989) vol. 26, pp. 1575-1578. |
| Haesslein, et al., “Recent Advances in Cyclin-Dependent Kinase Inhibition. Purine-Based Derivatives as Anti-Cancer Agents. Roles and Perspectives for the Future”, Current Topics in Medicinal Chemistry, 2:1037-1050 (2002). |
| Hearing Notice in Indian Patent App. No. 11241/DELNP/2014 mailed Jan. 24, 2020. |
| Heegaard, et al., “Affinity Capillary Electrophoresis: Important Application Areas and Some Recent Developments”, Journal ofChromatography B, 715:29-54 (1998). |
| Banks et al., Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFR inhibitor fortreatment of gastrointestinal stromal tumors, Sci. Transl. Med. 12, (2020). |
| Clinical trial NCT02571036—A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies—clinicaltrials.gov—Dec. 16, 2015. |
| Clinical trial NCT02571036—A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies—clinicaltrials.gov—Feb. 10, 2016. |
| Clinical trial NCT02571036—A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies—clinicaltrials.gov—Nov. 3, 2015. |
| Clinical trial NCT02571036—A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies—clinicaltrials.gov—Oct. 29, 2015. |
| International Search Report and Written Opinion from PCT/US2020/067557, mailed Apr. 23, 2021. |
| International Search Report and Written Opinion from PCT/US2020/067560, mailed Apr. 23, 2021. |
| Janku F. et al., “DCC-2618, a pan KIT and PDGFR switch control inhibitor, achieves proof-of-concept in a first-in-human study,” Late Breaking Abstracts, Plenary Session 6, Dec. 1, 2016, p. s4. |
| Lu Jiade et al., “Advanced in the targeted therapy of cancer: multi targeted Raf kinase inhibitor,” China Oncology, vol. 17, No. 1, (Dec. 31, 2007), pp. 1-7. |
| Office Action of U.S. Appl. No. 17/180,234 dated Apr. 29, 2021, 6 pages. |
| Office Action of U.S. Appl. No. 17/180,241 dated Aug. 20, 2021, 11 pages. |
| Office Action of U.S. Appl. No. 17/180,241 dated May 7, 2021, 9 pages. |
| Procenko, S.A., “Targeted Therapy in Melanoma, Gastrointestinal Stromal Tumors, Dermatofibrosarcoma Protuberans”, Practical Oncology, vol. 11, No. 3, https://practical-oncology.ru/articles/196.pdf, (2010), pp. 162-170. |
| Reardon, D. et al., “Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent gliosblastoma”, J. Neurooncol. (2011), 101: pp. 57-66. |
| Reis, R. et al., “Molecular characterization of PDGFR-α/PDGF-A and c-KIT/SCF in gliosarcomas”, Cellular Oncology, 2005; 27: pp. 319-326. |
| Remington, The Science and Practice of Pharmacy, Nineteenth Edition—1995, pp. 710-712. |
| Response to Office Action of U.S. Appl. No. 14/351,840 dated Sep. 28, 2015, 11 pages. |
| STN Registry Database RN 1225278-16-9. |
| Szucs, Z. et al., “Promising novel therapeutic approaches in the management of gastronitestinal stromal tumors”, Future Oncology, (2017), vol. 13(2), pp. 185-194. |
| Tanno, F. et al., “Evaluation of Hypromellose Acetate Succinate (HPMCAS) as a Carrier in Solid Dispersions”, Journal of Drug Development and Industrial Pharmacy, vol. 30, No. 1, pp. 9-17 (2004). |
| Vladimirova, L.U., “Usage of MEK Inhibitors in Oncology: Results and Perspectives”, Modern Natural Science Successes, No. 3, https://s.natural-sciences.m/pdf/2015/3/34730.pdf., (2015), pp. 18-30. |
| Zustovich, F. et al., “Sorafenib plus Daily Low-dose Temozolomide for Relapsed Glioblastoma: A Phase II Study”, Anticancer Research (2013), 33: pp. 3487-3494. |
| Shah, et al., “Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor,” Science (Jul. 16, 2004) vol. 305, pp. 399-401. |
| Shi, et al., “Abnormal Diels-Alder Reaction of 5-Alkoxythiazoles with Highly Reactive Dienophiles; 4-Phenyl-3H-1,2,4-triazole-3,5(4H)-dione, Diethyl Azodicarboxylate, and Diethyl Oxomalonate”, Bull. Chem. Soc. Jpn., 65:3315-3321 (1992). |
| Shinkai, et al., “Coenzyme Models, Part 45. Synthesis of Atropisomeric Flavins and their Novel Redox-induced Racemisation”, J. Chem. Soc. Perkin Trans., pp. 313-319 (1988). |
| Shiozaki, et al., “Impaired Differentiation of Endocrine and Exocrine Cells of the Pancreas in Transgenic Mouse Expressing the Truncated Type II Activin Receptor”, Biochimica et Biophysica Acta, 1450:1-11 (1999). |
| Sihto, et al., “KIT and Platelet-Derived Growth Factor Receptor Alpha Tyrosine Kinase Gene 1-30 Mutations and KIT Amplifications in Human Solid Tumors,” Journal of Clinical Oncology, 23(1):49-57 (2005). |
| Sircar, et al., “Synthesis of 4-Hydroxy-N-[5-{hydroxymethyl)-3-isoxazolyl]2-methyl-2H-1,2-bsnzo-thiazine-3-carboxamide 1, 1-Dioxide and [(5-Methyl-3-isoxazolyl)amino]oxoacetic Acid. Major Metabolites of Isoxicam,” J. Org. Chem. (1985) vol. 50, pp. 5723-5727. |
| Smith et al., “Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants,” Cancer Cell (2019), vol. 35, No. 5, pp. 738-759. |
| Stout, et al., “High-Throughput Structural Biology in Drug Discovery: Protein Kinases”, Current Pharmaceutical Design, 10:1069-1082 (2004). |
| Sugden, et al., ““Stress-Responsive” Mitogen-Activated Protein Kinases (c-Jun N-Terminal Kinases and p38 Mitogen-Activated Protein Kinases) in the Myocardium”, Circulation Research—Journal of the American Heart Association, 83:345-352 (1998). |
| Tanis, et al., “Two Distinct Phosphorylation Pathways Have Additive Effects on Abl Family Kinase Activation”, Molecular and Cellular Bioloav, 23(11 ):3884-3896 (2003). |
| Tarn, et al., “Analysis of KIT Mutations in Sporadic and Familial Gastrointestinal Stromal Tumors: Therapeutic Implications through Protein Modeling,” Clinical cancer research : an official journal of the American Association for Cancer Research, 11(10):3668-3677 (2005). |
| Teague, “Implications of Protein Flexibility for Drug Discovery”, Nature Reviews, 2:527-541 (2003). |
| Tian, et al., “Activating c-kit Gene Mutations in Human Germ Cell Tumors,” American Journal of Pathology, 154(6):1643-1647 (1999). |
| Tominaga, et al., “General model for Estimation of the Inhibition of Protein Kinases Using Monte Carlo Simulations”, J. Med. Chem., 47:2534-2549 (2004). |
| Tremblay, et al., “Efficient Solid-Phase Synthesis of Sulfahydantoins”, J. Comb. Chem., 4:429-435 (2002). |
| Tsuzuki, et al., “Synthesis and Structure-Activity Relationships of Novel ?-Substituted 1,4-Dihydro-4-oxo-1-(2-thiazolyl)-1,8-napthyridine-3-carboxylic Acids as Antitumor Agents. Part 2”, J. Med. Chem., 47:2097-2109 (2004). |
| Van Etten, “Cycling, Stressed-out and Nervous: Ceiiuiar Functions of c-Abi,” Trends in Cell Biology (May 1999) vol. 9, pp. 179-186. |
| Venter, et al., “The Sequence of the Human Genome”, Science, 291:1304-1351, Feb. 16, 2001; Erratum, Jun. 8, 2001. |
| Von Bubnoff, et al., “BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukemia to STI571. a prospective study,” The Lancet (Feb. 9, 2002) vol. 359, pp. 487-491. |
| Waetzig, et al., “Review Article: Mitogen-Activated Protein Kinases in Chronic Intestinal Inflammation—Targeting Ancient Pathways to Treat Modern Diseases”, Aliment Pharmacol Ther, 18:17-32 (2003). |
| Wan, et al., “Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF,” Cell (Mar. 19, 2004) vol. 116, pp. 855-867. |
| Wardelmann, “Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations,” The Lancet Oncology, 6(4):249-251 (2005). |
| Welker, et al., “Glucocorticoid-Induced Modulation of Cytokine Secretion from Normal and Leukemic Human Myelomonocytic Cells”, Int. Arch. Allergy Immunol, 109:110-115 (1996). |
| Wentland, et al., “3-Quinolinecarboxamides. A Series of Novel Orally-Active Antiherpetic Agents”, J. Med. Chem., 36:1580-1596 (1993). |
| Wilson, et al., “The Structural Basis for the Specificity of Pyridinylimidazole Inhibitors of p38 MAP Kinase”, Chemistry & Biology, 4(6):423-431 (1997). |
| Wilson, et el., “Laser-Jet Delayed Trapping: Electron-Transfer Trapping of the Photoenol from 2-Methylbenzophenone”, J. Am. Chem. Soc., 109:4743-4745 (1987). |
| Wolter, et al., “Copper-Catalyzed Coupling of Aryl Iodides with Aliphatic Alcohols”, Organic Letters, 4(6):973-976 (2002). |
| Wrana, et al., “Mechanism of Activation of the TGF-B Receptor”, Nature, 370:341-347 (1994). |
| Wu, et al., “Discovery of a Novel Family of CDK Inhibitors with the Program LIDAEUS:Structual Basis for Ligand-Induced Disordering of the Acivation Loop”, Structure, 11:399-410 (2003). |
| Yang, et al., “Molecular Mechanism for the Regulation of Protein Kinase B/Akt by Hydrophobic Motif Phosphorylation”, Molecular Cell, 9:1227-1240 (2002). |
| Yang, et al., “Palladium-Catalyzed Amination of Arly Halides and Sulfonates”, Journal of Organometallic Chemistry, 576:125-146 (1999). |
| Yarden, et al., “Human Proto-oncogene c-kit: a New Cell Surface Receptor Tyrosine Kinase for an Unidentified Ligand”, The EMBO Journal, 6(11):3341-3351 (1987). |
| Yoneda, et al., “A New Synthesis of Purines”, J.C.S. Chem. Comm., pq. 551 (1974). |
| Yonezawa, et al., “Synthesis of Sequentially Controlled Isomeric, Wholly aromatic Polyketones Composed of 2-trifluoromethylbiphenylene and 2,2′-dimethoxybiphenylene Units”, Reactive & Functional Polymers, 52:19-30 (2002). |
| Yoshimoto, et al., “Correlation Analysis of Baker's Studies on Enzyme Inhibition. 2. Chymotrypsin, Trypsin, Thymidine Phosphorylase, Uridine Phosphorylase, Thimidylate Synthetase, Cytosine Nucleoside Deaminase, Dihodrofolate Dehydrogenase, Glutamate Dehydrogenase, Lactate Dehydrogenase, and Glyceraldehydephosphate Reductase, Malate Dehydrogenase”, Journal of Medicinal Chemistry, 19(1 ):71-98 (1976). |
| Yoshino, et al., “Organic Phosphorous Compounds. 2. Synthesis and Coronary Vasodilator Activity of (Benzothiazolybenzyl) Phosphonate Derivatives”, J. Med. Chem., 32:1528-1532 (1989). |
| Yu, et al., “Frequency of TPR-MET Rearrangement in Patients with Gastric Carcinoma and in First-Degree Relatives”, Cancer, 88(8):1801-1806 (2000). |
| Zaidi, et al., “New Anti-Mycobacterial Hydantoins”, Pharmazie, 35:755-756 (1980). |
| Zhen, et al., “Structural and Functional Domains Critical for Constitutive Activation of the HGF-Receptor (Met)”, Oncogene, 9(6):1691-1697 (1994). |
| Zinner, et al., “Zur Weiteren Kenntnis Bicyclischer 3.5-Dioxopyrazolidine”, Die Pharmazie, 25(5):309-312 (1970). |
| Zvilichovsky, et al., “Aminolysis and Polymerization of 3-(p-Toluenesulfonoxy) Hydantoin”, Israel Journal of Chemistry, 7:547-554 (1969). |
| Assessment Report for Tukysa (tucatinib), European Medicines Agency, Dec. 10, 2020. |
| Deciphera Pharmaceuticals: “Highlights of Prescribing Information These highlights do not include all the information needed to use Qinlock safely and effectively. See full prescribing information for Qinlock,” (May 1, 2020), retrieved from internet: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf, 18 pages. |
| International Preliminary Report on Patentability of PCT/US2022/028456 dated Nov. 23, 2023, 10 pages. |
| Janku, F. et al., “Phase 1 study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma,” ESMO Congress Virtual Meeting, (Sep. 16, 2021), p. 1. |
| Janku, F. et al., “Phase I study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma,” Annals of Oncology, vol. 32, (Sep. 1, 2021), p. S896. |
| Janku, F. et al., “Ripretinib Demonstrates Impressive Efficacy, Durability in Heavily Pretreated KIT-Mutated Melanoma,” (Dec. 6, 2021), retrieved from https://www.onclive.com/view/ripretinib-demonstrates-impressive-efficacy-durability-in-heavily-pretreated-kit-mutated-melanoma, access on Feb. 5, 2024. |
| Kalinsky, K. et al., “A Phase II Trial of Dasatinib in Patients with Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2607),” American Cancer Society, vol. 123, No. 14, (Mar. 23, 2017), pp. 2688-2697. |
| Li, X. et al., “Effect of hepatic impairment on the pharmacokinetics of ripretinib,” Journal of Clinical Oncology, V. 40, No. 16, suppl., e16031, (2022), 1 page. |
| Pham, D. M. et al., “KIT and Melanoma: Biological Insights and Clinical Implications,” Yonsei Medical Journal, vol. 61, No. 7, (Jul. 1, 2020), pp. 562-571. |
| Protsenko, S.A., “Targeted Therapy in Melanoma, Gastrointestinal Stromal Tumors, Dermatofibrosarcoma Protuberans”, Practical Oncology, vol. 11, No. 3, (2010), pp. 162-170. |
| Number | Date | Country | |
|---|---|---|---|
| 20200352920 A1 | Nov 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62624453 | Jan 2018 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/US2019/016161 | Jan 2019 | WO |
| Child | 16943871 | US |
